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ABSTRACT 
Gene therapy has emerged as a promising strategy for the treatment or prevention of 
many acquired or genetic diseases that are considered incurable at the present time. Although 
viral and non-viral vector approaches are the major techniques employed for somatic gene 
transfer, non-viral vectors (cationic liposomes, dendrimers, chitosans, polymers & 
surfactants) have attracted great interest recently, due to their unique properties. A number of 
non-viral carriers have been extensively investigated and developed in recent years for 
targeted drug delivery or gene therapy in various pre-clinical/clinical trials. Despite this, the 
quest for new non-viral carriers with improved transfection and low toxicity is still 
proceeding, driven by a need to overcome safety concerns associated with viral vectors. Of 
the non-viral vectors, an intriguing class of building blocks which has elicited extensive 
interest are the third generation di-cationic surfactants: a class of bis-surfactants called 
“gemini surfactants (GSs)”. The interest is due to their unique self-assembly, hundredfold 
lower CMC (compared to their monomeric counterparts), thousand-fold improved surface 
activity, and ability to form a rich array of aggregate morphologies. In this project, the effect 
of various inorganic and organic counterions on micellization was studied and analyzed at 
air–water surfaces as well as in bulk solutions. Additionally, the size & zeta potential of the 
nanoparticles, and the in vitro transfection efficiency studies in human ovarian cancer cell 
lines were also analysed to investigate the dominant influence of the anions on the 
aggregation behavior and DNA delivery efficiency of eight surfactants of the ethanediyl-α,ω-
bis-(dimethylhexadecyl-ammonium) type, [C16H33(CH3)2-N-(CH2)2-N-(CH3)2C16H33].2X
–
 
referred to as gemini 16-2-16; where X refers to the counterion were studied. Counterions of  
chloride (Cl
–
), bromide (Br
–
), ½ malate (C4H4O5
– –
), ½ tartrate (C4H4O6
– –
), adenosine mono 
phosphate, AMP (C10H13N5O7P
–
), guanosine mono phosphate, GMP (C10H13N5O8P
–
), 
cytidine mono phosphate, CMP (C9H13N3O8P
–
), and uridine mono phosphate, UMP 
(C9H12N2O9P
–
) were investigated and were classified into three different categories 
depending on their nature: (1) small inorganic counterions [chloride (Cl
–
), and bromide (Br
–
)] 
taken from the Hofmeister series were studied to focus on the effect of ion type; (2) 
Hydroxy-alkyl di-carboxylate counterions [malate (C4H4O5
– –
), and tartrate (C4H4O6
– –
)] were 
studied to focus on the effect of the hydrophilicity of counterions; and (3) heterocyclic ring 
containing nucleotide mono phosphate counterions were included to focus on mainly self-
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assembly and other parameters. We demonstrate the influence of different anions associated 
with this 16-2-16 series of gemini by analyzing the effect of counterions on the micellization 
and aggregation behavior of these gemini surfactants, characterized by determination of the 
critical micelle concentration (CMC), degree of micelle ionization (α), and free energy of 
micellization (ΔGM) and are discussed in terms of the hydrophilicity of anions, counterion 
hydration, interfacial packing of ions, and ionic morphology. Our results clearly revealed that 
a counterion effect on micellization and aggregate morphology, attributed to the balancing 
and controlling forces of the counterions to the surfactant itself. Hydrogen bonding among 
the –OH groups of the counterions (where applicable) and water molecules, as well as the 
strong hydrophobic interaction among the hydrocarbon side chains is postulated to be the 
main origins for the unique aggregation behaviors of these gemini surfactants. These 
amphiphiles can form both micelles and vesicles spontaneously with a micelle-to-vesicle 
transition at a concentration above the respective CMC. Furthermore, the size & zeta 
potential characterizations along with the in vitro transfection data manifest the significant 
impact of counterions on the GSs as therapeutic drug delivery carrier. Our transfection 
efficiency (TE) data also demonstrated that the surface charge density of the particles formed 
by the GSs is the predominant factor for cellular uptake and consequent TE of the respective 
GSs. 
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CHAPTER-1: INTRODUCTION 
1 
 
1. Introduction 
1.1 Gene therapy background 
Gene therapy (GT) represents a new paradigm for not only the therapeutic treatment 
of human genetic diseases, but also for drug delivery. Due to its potential for treating chronic 
disease and genetic disorders, gene therapy has drawn increasing attention in the medical, 
pharmaceutical and biotechnological sciences [1]. The purpose of gene therapy is to achieve 
a desired therapeutic effect in the treatment of a given disease, by delivery of a gene or genes 
in order to enable cells to generate therapeutic proteins [2]. Commonly, gene therapy 
involves the administration of nucleic acids (specific gene expression cassettes) with a 
specific delivery vehicle (also known as a vector) for the purpose of treating diseases 
associated with the absence, abnormal expression, or overexpression of specific genes or 
genetic elements by replacing, correcting or repressing the gene of interest [3-5]. Essential 
components for current gene therapy includes: a) an effective therapeutic gene that can be 
expressed at a target site, and b) an efficient and safe delivery system (vector) that delivers 
the therapeutic genes to a specific target tissue or organ [6]. Globally, two major types of 
gene therapy applications are widely accepted: viral vector mediated and non-viral vector 
mediated gene delivery.  Each will be described in detail in the following sections. 
 
1.1.1 Recent advances in viral vector based GTs 
Viral vectors are the most efficient vectors currently being studied [7]. There are over 
1,800 approved gene therapy clinical trials with viral vectors accounting for approximately 
two-thirds of all trials by June 2012 [8]. As of January 2014, 1,996 clinical trials were 
undertaken in 34 countries where approximately 72 % of the delivery systems employed are 
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different viral vectors (Figure-1.1) [9]. Viral vector assisted gene therapy technique exploits 
the natural ability of viruses to introduce their genetic cargo to the target cells, and depends 
on molecular biology methods to replace essential genes for viral replication, assembly, or 
infection [10].  
Adenoviral vectors are the most commonly used viral vector due mainly to their high 
transfection efficiency, high expression, and infection of non-dividing cells [8]. For instance, 
in 2003 the State Food and Drug Administration of China approved gene therapy treatment, 
Gendicine (by SioBiono GeneTech), which utilized a recombinant human adenovirus to 
deliver the p53 tumor suppressor gene for the treatment of head and neck squamous cell 
carcinoma (HNSCC). Gendicine is the world’s first approved gene therapy product that has 
had tremendous success for cancer treatment [4, 7]. Additionally, in 2005, China also 
approved Onocorine (Sunway Biotech Co. Ltd), a conditionally replicative recombinant 
adenoviral vector for the treatment of late stage refractory nasopharyngeal cancer [4]. In the 
same year (September 2005), the State Food and Drug Administration of China approved a 
second drug based on gene therapy, Endostar, for treatment of cancerous tumours in the 
lungs and other organs [11]. The only adenoviral vector that has completed a phase-III 
clinical trial for the first time in European Union/Commission (EU/EC) was Cerepro (Ark 
Therapeutics Group plc), in 2008 [4]. Finally, in 2012 EC approved the gene therapeutic 
“Glybera” (UniQure), an adeno-associated viral vector delivering human lipoprotein lipase 
gene in muscle tissue for the treatment of lipoprotein lipase deficiency [4, 12, 13].  
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Figure-1.1: Different vectors used in GT clinical trials as of January 2014 (adapted from 
[9]). 
 
 
1.1.2 Safety concern associated with viral vectors in GTs 
Viruses are highly evolved biological machines that efficiently gain access to host 
cells and exploit their cellular machinery to facilitate their own replication. Ideal virus-based 
vectors for most gene-therapy applications harness the viral infection pathway but avoid the 
subsequent expression of viral genes that leads to replication and toxicity. This is achieved 
by deleting all, or some, of the coding regions from the viral genome, but leaving intact those 
sequences that are required in cis for functions such as packaging the vector genome into the 
virus capsid or the integration of vector DNA into the host chromatin [14, 15]. There are a 
total five types of viral vectors (Table-1.1) that are available for gene therapy pre-clinical & 
clinical trials [14, 16]. These five classes of viral vector can be categorized in two groups 
according to whether their genomes integrate into host cellular chromatin (oncoretroviruses 
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and lentiviruses) or persist in the cell nucleus predominantly as extrachromosomal episomes 
[adeno-associated viruses (AAVs), adenoviruses (Ad) and herpes viruses] [14]. Table-1.1 
summarizes the advantage and disadvantages of these viral vectors for gene therapy [14, 17]. 
Although the viral based vectors are most widely used due to their high delivery efficiency of 
DNA,  their usage sometimes poses severe safety concerns due to potential induction of 
undesired immunostimulatory responses and/or insertional mutagenesis [14]. Other 
limitations of viral vectors include the size of the therapeutic gene, production and packing 
problems, as well as high cost of production [7, 18-20]. 
 
Among the 5 classes of viral vectors, adenoviral vectors are known to be extremely 
efficient and unfortunately, most immunogenic [14, 21]. The majority of recombinant 
adenoviral vectors are based on human adenovirus serotypes 2 (Ad2) and 5 (Ad5) of species 
C [15, 22]. It has been reported that adenovirus-mediated cancer gene therapy showed only 
limited efficacy & less targeting in a number of preclinical and clinical studies [22]. Again, 
the use of first generation adenoviral vectors in vivo is associated with the induction of both 
innate and acquired immune responses [22, 23]. Cytotoxic T-lymphocyte (CTL) responses 
can be elicited against viral gene products or ‘foreign’ transgene products that are expressed 
by transduced cells [14].  
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Table-1.1: The main group of viral vectors (modified from [14, 17]) 
Vector 
Genetic 
Material 
Packaging 
Capacity 
Particle 
Size 
Inflammatory 
Potential 
Main 
Limitations 
Main 
Advantages 
Enveloped 
Retrovirus RNA 8 kb 100 nm Low 
Only transduces 
dividing cells; 
integration might 
induce oncogenesis 
in some applications 
Persistent gene 
transfer in 
dividing cells 
Lentivirus RNA 8 kb 100 nm Low 
Integration might 
induce oncogenesis 
in some applications 
Persistent gene 
transfer in most 
tissues 
HSV-1 dsDNA 
40 kb* 
150 kb** 
150 – 200 
nm 
High 
Inflammatory; 
transient transgene 
expression in cells 
other than neurons 
Large packing 
capacity; strong 
tropism for 
neurons 
Non-enveloped/Naked 
AAV ssDNA <5kb 
20 – 25 
nm 
Low 
Small packaging 
capacity 
Non-
inflammatory; 
non-pathogenic 
Adenovirus dsDNA 
8 kb* 
30 kb*** 
70 – 100 
nm 
High 
Capsid mediates a 
potent inflammatory 
response 
Extremely 
efficient 
transduction of 
most tissues 
 
*Replication defective. **Amplicon. ***Helper dependent. AAV: Adeno-associated viral vector; dsDNA: Double-stranded 
DNA; HSV-1: Herpes simplex virus-1; ssDNA: Single-stranded DNA. 
 
 
 
The adenoviral capsid itself induces humoral virus-neutralizing antibody responses 
[14] and the same capsid proteins trigger an acute inflammatory response characterized by 
the rapid release of inflammatory cytokines, including interleukin-6 (IL-6) and IL-8, and the 
recruitment of immune effector cells, such as neutrophils, into the liver [22]. These 
inflammatory responses to the adenovirus capsid increase linearly with an escalation in 
vector dose. This vector dose-toxic response relationship is characterized by a ‘threshold 
effect’ in dose-escalation studies indicating that cellular toxicity occurs over a narrow dose 
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range and often no symptoms are observed until a slightly higher vector dose is administered, 
which induces severe cellular injury [14]. 
The potential and promising development of these viral vectors has been 
unfortunately overshadowed to a great extent due to these limitations as mentioned, and most 
importantly due to the reports of patient mortality in clinical trials that use viral vectors for 
gene therapy [8, 24-27]. Such an example is represented by the tragic death of Jesse 
Gelsinger in September 1999, a 18 year old male patient in phase-I gene therapy clinical trial 
(led by Dr. James M. Wilson) at University of Pennsylvania for an adenoviral (attenuated, 
recombinant, 3
rd
 generation) vector based therapeutic treatment for his partial ornithine 
transcarbamylase (OTC) deficiency [14, 16, 27-30].  
OTC is a metabolic/liver enzyme that is required for the safe removal of excessive 
nitrogen from amino acids and proteins [14]. The genetic nature of the disease prompted a 
GT approach and the use of adenoviral vectors as a viable option. The vector had been 
infused directly into the liver through the hepatic artery, and this systemic delivery of the 
vector triggered a massive inflammatory response that led to disseminated intravascular 
coagulation, acute respiratory distress and multi-organ failure, and the eventual death of the 
subject [14, 29]. Autopsy reports later indicated vector induced activation of innate immunity 
as the main cause of death [30]. 
Insertional mutagenesis is another potential safety concern that has been documented 
in an ex vivo GT strategy to treat X-linked severe combined immunodeficiency (SCID-Xl) 
using a γ-retroviral vector [8, 25, 27, 29]. The term ‘severe combined immunodeficiency’ 
(SCID) was coined to indicate rare, lethal conditions in which infants die from an array of 
infections associated with a lack of lymphocytes in the blood [25].  
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A total of 20 patients suffering from SCID-Xl were treated with a γ-retroviral vector 
to correct the genetic defect from 1999 to 2009, achieving an impressive 85% success rate 
[25]. In the SCID-Xl trial, haematopoietic stem cells were genetically reconstituted with the 
γ-chain cytokine receptor and went through many cell divisions to generate a repopulating 
functional T-cell repertoire [14].  Unfortunately, a quarter (5 out of 20) of these patients were 
later found to have developed T-cell leukemia [25]. The development of T cell leukemia was 
attributed to the uncontrolled proliferation of T-cells due to vector integration near the LMO2 
proto-oncogene promoter, a phenomenon known as insertional mutagenesis leading to 
subsequent aberrant expression of oncogenes [8]. 
 
1.1.3 Non-viral vectors: Are they superior? 
As described above, the resulting complications from the employment the viral 
vectors has created controversy regarding their use in human gene therapy applications [24, 
26] and thus there is large body of research devoted for the quest of suitable non-viral 
vectors. Among the three major class of non-viral delivery systems – naked DNA, physical 
delivery, and chemical delivery via synthetic vectors (called non-viral vectors hereafter), the 
non-viral vectors, typically comprised of a mixture of cationic and neutral lipids, are 
generally non-toxic, non-immunogenic, are not limited in the size of gene they can 
encapsulate, are relatively cheap and easy to produce, and allow for specialized delivery 
options (such as targeted delivery, time-dependent release, and enhanced circulation times) 
[7, 19, 31-33].  
A wide variety of commercial transfection systems based on non-viral delivery 
systems are available for in vitro cell studies [34-37]. As shown in Table-1.2, most of the 
commercial transfection systems employ a non-viral delivery system, rather than a viral 
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vector for use in transfection. From the data published in January 2014 (Figure-1.5) only 5.5 
% of the vectors were lipid based (non-viral) [9].  Although in low percentage, this data 
reveals a promising application for non-viral gene delivery in ex vivo applications, instead of 
in vivo therapies as outlined in Table-1.2 [23]. A major reason for this discrepancy in the 
usage of viral versus non-viral vectors is the resulting transfection efficiency. Unlike viral 
vectors which possess inherent mechanisms to bypass the cellular defenses of the host, non-
viral delivery systems do not have such mechanisms and currently have in vivo issues which 
are related to pharmacokinetics and intracellular barriers [38, 39]. 
Table-1.2: List of commercially available in vitro transfection reagents [34-37]. 
Name Formulation Manufacturer 
Non-viral 
Convoy™  Cationic Polymer  ACTgene  
GeneCellin™  Cationic Polymer  Bio Cell Challenge  
Lipofectamine
® 
 Cationic Lipid  Invitrogen  
Effectene  Non- liposomal  Qiagen  
Superfect  activated dendrimer  Qiagen  
Fugene 6
®
  Non-liposomal  Promega  
TransIT  Not disclosed  Mirus Bio  
TransFast™  Synthetic cationic lipid  Promega  
JetPEI
®
  PEI  Polyplus Transfection  
ExGen 500™  Linear PEI  Fermentas/Thermo Sci  
TurboFect  Cationic Polymer  Fermentas/Thermo Sci  
Escort™  Cationic Liposome (DOTAP DOPE 1:1)  Sigma Aldrich Co. LLC.  
NeuroPORTER™  Cationic lipid  Genlantis  
HiFect
® 
 Biochemical trasnfection agent  Lonza  
X-tremeGENE  Non-liposomal reagent, synthetic  Roche  
Genejuice
®
  Not disclosed  Millipore  
Glycofect  Not disclosed  Kerafast  
Viral  
SMARTvector  Lenti Virus  Thermo Sci  
Virapower™  Adenovirus or lentivirus  Invitrogen  
Polybrene
®
  Retrovirus  Millipore  
rAVE™  AAV  Gene Detect  
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Unfortunately, this major limitation i.e. low transfection efficiency (TE) of non-viral 
vectors must be overcome for such systems to be recognized as the ideal vehicles for gene 
delivery [7, 33, 40]. The low TEs associated with non-viral delivery systems are directly 
attributed to the various barriers encountered by those vectors (discussed later) during the 
process of gene delivery. Table-1.3 illustrates a comparison of the advantages and 
disadvantages between viral and non-viral vectors in gene therapy. Literature suggests that 
cationic amphiphiles are considered to be promising alternatives for viral vectors in gene 
therapy [7, 41]. Thus, extensive research is necessary in this field concerning the mechanism 
of overcoming the delivery barriers for non-viral vectors for the rational design of suitable 
non-viral delivery systems for clinical use [39, 42-44]. 
The discussion of all the available nonviral vectors is beyond the scope of this thesis. 
Between the two most widely used synthetic non-viral vectors – namely cationic lipids & 
cationic polymers – only the cationic lipids (also known as cytofectins [45]) will be discussed 
in this dissertation. For non-viral gene delivery, the role of a synthetic based vector is to bind 
with therapeutic DNA sufficiently and rapidly, then to penetrate the target cell where the 
vector releases the DNA from the complex and then uptake of DNA by the nucleus [19, 46-
49]. The first, key step in the whole process is the compaction of DNA into a positively 
charged (or neutral) particle small enough to be taken up by the negatively charged cell [18, 
19, 48, 49]. This generally requires a synthetic chemical species bearing multiple positive 
charges to replace the monovalent counterions of DNA [48].  
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Table-1.3: Comparison between viral and non-viral vector mediated gene therapy [33] 
Viral vectors Non-viral vectors 
High transfection efficiency  Low transfection efficiency  
High production cost  Inexpensive  
Limitations in scale up  Easily produced on large scale  
Limited cargo size  Unrestricted by plasmid size  
Immunogenic  Low immunogenicity  
Potential for oncogenesis  Very low toxicity  
 
 
1.1.3.1 Cationic lipid based non-viral vectors 
Among the non-viral gene delivery vectors, lipid-based vectors are the most widely 
used non-viral gene carriers. It was first shown in 1980 that liposomes composed of the 
phospholipid phosphatidylserine could entrap and deliver SV40 DNA to monkey kidney cells 
[50]. Felgner et al. in 1987 was the first group who reported a synthetic species which 
effectively binds and delivers DNA to cultured cells; a double-chain monovalent quaternary 
ammonium lipid, N-[1-(2,3-dioleyoloxy)propyl]-N,N,N-trimethyl ammonium chloride 
(DOTMA) [6, 51, 52]. Later on, DOTMA was used in the development of the first 
commercialized reagent, Lipofectin
TM
 (Invitrogen), applied for lipid-based transfection or 
lipofection. After that initial breakthrough, many macromolecular and supramolecular 
cationic systems have been developed aiming to employ them as non-viral vectors to achieve 
better transfection efficiencies. These compounds include notably, cationic polyelectrolytes 
such as diethylaminoethyl-dextran (DEAE-D), polylysine, polyethylene-imine, 
polynorbornane, and polyamine dendrimers. The supramolecular systems of particular 
interest are those that form amphiphile aggregates, most commonly liposomes [48].  
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The amphiphilic compounds usually have two basic parts in their structural 
backbones – the head and the tail groups. They can differ by the number of charges on the 
head groups, along with differing in other structural modifications within the molecules. 
Generally, the hydrophilic head group of the cationic lipids commonly consists of a 
combination of phosphate and amine groups whereas, the hydrophobic domain is composed 
of two types of hydrophobic moieties including aliphatic chains, cholesterol, and/or other 
variations of steroid rings [19]. The linker - commonly consisting of ether, ester, carbamate, 
or amide bonds - determines the flexibility, stability, and biodegradability of the cationic 
lipid [53].  In most cases, the polar head group of a monomeric cationic amphiphiles / lipids 
consist of positively charged monovalent quaternary ammonium salts/ions, QAS [such as, in 
DTAB, TTAB, CTAB (Figure-1.2), and 1,2-dioleoyloxypropyl-N,N,N-trimehtylammonium 
chloride, DOTAP (Figure-1.3)]. The lipophilic moieties (tails) of the many of these lipids are 
connected to the hydrophilic core or the “head group” via an ether linkage rather than an 
ester linkage, since cationic lipids with an ether linkage – such as DOTMA, have been shown 
to display higher transfection efficiency in vitro and in vivo (also showing higher 
cytotoxicity) compared to their corresponding ester analogues, such as DOTAP [54-56].  
Other commercially available  transfection reagents (Figure-1.3) include N,N-
dimethyl-N-[2-(spermine–carboxamido) ethyl]-2,3-bis(dioleyloxy)-1-propanaminium penta-
hydro chloride (DOSPA), 1,3-dioleoyloxy-2-(6-carboxy–spermyl)-propyl–amide (DOSPER), 
dimethyl–dioctadecyl–ammonium bromide (DDAB), N,N-dioleyl-N,N-dimethyl–ammonium 
chloride (DODAC) usually in combination with fusogenic/helper lipids like 1,2-dioleoyl 
phosphatidyl–ethanolamine (DOPE) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) 
[52] (Figure-1.3). DOSPER, DOGS (Di-octadecyl-amido-glycyl-spermine), and DOSPA are 
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three examples of cationic lipids with modified head groups derived from the polyamine 
called spermine. The increased cationic groups in these multivalent lipids promote stronger 
DNA interaction for enhanced delivery. Modification of the alkyl tail such as replacement of 
the tail(s) with the application of cholesterol derived cationic lipids, DC-Chol (3β-[N-(N',N'-
dimethylaminoethyl) carbamoyl] cholesterol), was shown to promote better stability and 
reduced cytotoxicity for improved transfection efficiencies in vitro [57]. 
 
     .  -                                                                                - 
 
DTAB      TTAB 
              - 
 
CTAB 
 
Figure-1.2: Molecular structures of DTAB, TTAB, and CTAB showing the positively 
charged quaternary ammonium moiety in the head groups. 
 
 
 
Cationic lipids can compact and stabilize DNA by a combination of intermolecular 
attractive electrostatic interactions between the opposite charges, and intermolecular 
hydrophobic interactions between the apolar hydrocarbon skeletons [48, 58]. As a result of 
these interactions, the DNA is condensed into smaller aggregates where it is protected from 
endogenous nucleases; while the hydrophobic elements of the aggregate may also promote 
escape from the endosome by fusion or aggregation with the endosomal membrane [48]. The 
in vitro transfection efficiency of these lipids depend mainly on the structure, usage of other 
helper lipids (such as DOPE, for assisting endosomal escape), the N
+
/P
–
 ratio (i.e. charge 
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ratio) of the lipids to DNA, the size and magnitude of the charge of the lipoplex, and the type 
of cell lines under treatment. Limitations of cationic lipids include low efficacy owing to 
poor stability and rapid clearance, as well as the generation of inflammatory or anti-
inflammatory responses [50]. Recently, Allovectin-7, which is a locally administered for-
mulation consisting of (±)-N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-
propanaminium bromide (DMRIE) – DOPE and a DNA plasmid, failed to meet its efficacy 
end points in a Phase III clinical trial for treatment of advanced metastatic melanoma [50]. 
Nonetheless, various liposomal formulations continue to be developed clinically, including 
DOTAP– cholesterol, Vaxfectin® and GL67A–DOPE– DMPE–polyethylene glycol (PEG) 
(Table-1.4) [50]. Notably, the new cytofectin formulation, Vaxfectin
®
 which is composed of 
(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium 
bromide (GAP-DMORIE) and the co-lipid, 1,2-diphytanoyl-sn-glycero-3-
phosphoethanolamine (DPyPE), has shown significant enhancement of humoral immune 
responses against pDNA encoded antigens compared with naked pDNA [45].  
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Figure-1.3: Structures of commercially available lipids DOTMA, DDAB, DOTAP, 
DODAC, DOSPA, DOSPER (reused with permission from [52]. Copyright [2005], Elsevier) 
and the neutral helper lipids DOPE & DOPC (reused with permission from [59]. Copyright 
[2004], Elsevier). 
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Table-1.4: Non-viral DNA vectors under clinical evaluation (modified from [50]) 
Delivery system GT drug Indications Phase Status 
DOTAP– cholesterol  
DOTAP– 
Chol-fus1  
Non-small-cell lung 
cancer  
I Completed 
I/II Active 
GAP-DMORIE– 
DPyPE  
Tetravalent dengue 
vaccine  
Dengue disease vaccine  I Active 
GL67A–DOPE– 
DMPE–PEG  
pGM169/GL67A  
 
Cystic fibrosis  II Active 
PEI  
BC-819/PEI  Bladder cancer  II Active 
BC-819  Ovarian cancer  I/II Completed 
DTA-H19  Pancreatic cancer  I/II Completed 
SNS01-T  
Multiple myeloma and B 
cell lymphoma  
I/II Recruiting 
CYL-02  
Pancreatic ductal 
adenocarcinoma  
I Completed 
PEG–PEI– cholesterol  
EGEN-001  
Ovarian, tubal and 
peritoneal cancers  
I Recruiting 
II Active 
EGEN-001-301  
Colorectal peritoneal 
cancer  
I/II Recruiting 
PEI–mannose– 
dextrose  
DermaVir/LC002  HIV vaccine  II Active 
Poloxamer CRL1005– 
benzalkonium  
Chloride 
ASP0113  CMV vaccine  
III Recruiting 
II Recruiting 
VCL-CB01  CMV vaccine  II Completed 
 
 
1.2 Potential barriers to non-viral vector mediated GT 
 Generally, the process by which plasmids are delivered to targeted cells is known as 
transfection. Current non-viral gene therapy involves local or systemic administration of 
plasmid DNA (pDNA) which encodes for a transgene gene which yield expression of a 
therapeutic protein, thereby correcting a disease state. The non-viral DNA delivery vectors 
(Figure-1.4) [60] generally consist of the therapeutic nucleic acid (the pDNA), a cationic 
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molecule (polymer or lipid) with a neutral helper lipid (in some cases, to overcome the 
transfection barriers), targeting ligands, nuclear localization signals (NLS) and stealth groups 
[18]. As mentioned earlier, the most widely used non-viral vectors are those consisting of 
either cationic lipids (which form “lipoplexes” with deoxyribonucleic acid, DNA) or cationic 
polymers (forming “polyplexes” with DNA) [61]. There are a number of barriers (Figure-1.5) 
– both extracellular, and intracellular – based on several review articles [49, 62-77], that can 
hinder the transfection process which in turn can affect the overall efficiency of gene 
delivery.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1.4: Basic building block of a non-viral gene delivery system. Non-viral delivery 
systems are composed of three fundamental elements. The first is the nucleic acid that forms 
core of the NP. Second, is the soft material that forms the basic element of the NP and 
encapsulate the DNA into a NP. Finally additional functional groups can be added to the base 
NP to augment the system and improve overall efficacy (reused from [60] through the 
permission of author) 
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Briefly, the extracellular barriers consist of vector instability due to components 
within the blood, adhesion to non-targeted tissues, phagocytosis of vector by macrophage, 
and DNA-degradation [73] In blood circulation, the vector-DNA complexes must evade 
uptake by macrophages, clearance by renal filtration, and must have improved ability to 
circumvent the RES (reticulo-endothelial system) and degradation by endogenous nuclease 
[78]. They need to traverse from blood vessels to target tissues followed by subsequent 
translocation into the cells impacting mitochondrial respiration, ATP synthesis, activity of 
drug efflux transporters, apoptotic signal transduction, and gene expression [78]. Despite 
some tissues such as tumors, inflammatory sites and the RES (e.g., liver, spleen) with leaky 
blood vessels, the capillary vessel walls in most organs and tissues are impermeable to large 
nucleic acids. Furthermore, extracellular matrix (ECM) resists the movement of gene 
medicines to target cells due to its dense polysaccharides and fibrous proteins [73]. The 
intracellular barriers include cellular internalization of the vector (cell membrane itself is a 
major barrier), escape from the endosome and delivery in the cytoplasm, dissociation of the 
nucleic acid-vector complex, cytosolic trafficking of nucleic acid, and nuclear entry of the 
DNA cargo [18, 73]. 
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Figure-1.5: Extracellular and intracellular barriers to gene delivery: A) Degradation of 
unprotected, naked pDNA vectors by nucleases upon systemic delivery; B) Removal of 
synthetic vectors by the reticuloendothelial system; C) Significant aggregation with blood 
components leading to vessel obstruction; D) Extravasation of naked pDNA and synthetic 
vectors across the endothelial wall and extracellular matrix; E) Repulsive forces between 
naked pDNA vectors and cell membrane inhibit effective cellular uptake and internalization; 
F) Lysosomal degradation of synthetic vectors and DNA cargo in absence of endosomal 
escape; G) Degradation of released DNA cargo by intracellular nucleases; H) Nuclear 
membrane obstructing nuclear entry and transgene expression (reused from [79] through the 
permission of the author). 
 
 
 
1.3 Gemini surfactants as non-viral vectors 
Surface active agents, commonly called “surfactants” are a special class of 
amphiphilic compounds possessing characteristic physicochemical properties at two 
immiscible interfaces and in bulk solution [80]. Surfactants (cationic, anionic, or non-ionic) 
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are versatile materials used in numerous products for purposes including motor oils, 
pharmaceuticals, detergents and petroleum, as floating aids for applications, and in high-
technology areas like mining, petroleum, chemical, biochemical research, electronics, 
printing, magnetic recording, biotechnology and microelectronics [81, 82]. As surfactants are 
utilized extensively throughout the world every day, the quest for high-efficiency, 
environment friendly novel surfactants is ongoing.  
Classic surfactant molecules are generally composed of two distinct parts in their 
molecular structure: one polar head group and a nonpolar alkyl chain or tail. Due to this dual 
polar-non polar character, surfactant molecules are often termed as “amphiphiles” [80, 81]. 
When surfactants are dissolved in water, their hydrophobic groups are directed away from 
the water and the free energy of the solution is minimized through a phenomenon called the 
“hydrophobic effect” [83]. Due to their amphiphilicity, surfactant molecules tend to also be 
adsorbed at the interface of two immiscible phases (Figure-1.6) to decrease the surface and 
interfacial tension.   Alternatively they can self-aggregate to form well-developed supra-
molecular assemblies, called micelles (if present above a certain concentration, known as the 
critical micelle concentration, CMC) as a means of minimizing unfavorable energies [80, 81, 
84].  
From extensive investigations of bis-surfactants a synthetic amphiphile called 
“gemini surfactants” (GSs), was developed. In 1991, Menger et al. first coined the term 
“Gemini” meaning “twin or dimer” to describe these bis-surfactants having a rigid spacer 
such as benzene or stilbene [48, 85, 86]. The terminology has since been extended to 
encompass any other bis or double tailed (dimeric) surfactants, irrespective of the nature of 
the spacer [7, 87], as well as surfactants with two or more head groups with any number of 
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tails [88, 89].  These dimeric gemini surfactants are composed of two monomeric 
amphiphilic moieties connected at or near the head group by a spacer or linker group. The 
spacer can be short or long, composed of methylene groups, rigid (stilbene), polar (polyether) 
or non-polar (aliphatic, aromatic) groups. The polar head group can be positive (ammonium), 
negative (phosphate, sulphate, carboxylate) or non-ionic and may be polyether or sugar [6, 7, 
48, 55, 85, 86, 89-94].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1.6: Schematic representation of typical adsorption and formation of aggregates by 
self-assembled amphiphiles (adapted from [83]). 
 
 
In addition to structural variables associated with simple surfactants (such as tail 
length and degree of branching, ionic nature of the head group, and counterion type), GSs are 
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also characterized by the number of heads (dimer, trimer, tetramer, etc.), and spacer 
solubility (i.e., hydrophilic or hydrophobic) [6, 88, 89]. Gemini analogues of lipids (also 
called gemini lipids) have also been reported, which possess multiple head groups and at 
least four or more hydrophobic chains as shown in Scheme-1.1 [6, 88]. The great majority of 
gemini structures are symmetric with two identical polar groups and two identical chains. 
The most commonly studied series of GS is the N,N’-bis (dimethylalkyl)-alkane-
diammonium-dibromide series, or “m-s-m” DMA type gemini surfactants (DMA=dimethyl 
ammonium, the m in this notation refers to the number of carbon atoms in the alkyl tails, 
while s refers to the number of atoms making up the spacer group) [6, 7, 48, 55, 85, 91, 95]. 
However, unsymmetrical gemini molecules and GS with three or more polar groups or tails 
have also been reported [6, 96, 97].  
Gemini surfactants possess unique properties that directly result from their novel 
structure, such as a critical micelle concentration (CMC) that is 10 – 100 orders of magnitude 
lower than their monomeric counterparts, a thousand-fold increase in surface activity, greater 
efficiency in lowering the surface tension, lower Kraft temperature, better solubilization, 
better wetting, viscoelasticity, gelification, and shear thickening than the corresponding 
conventional monomeric surfactants [7, 80, 81, 84, 92, 94, 98-100].  
Due to their unique properties, gemini surfactants have wide applications in skin care 
formulations, templates for the synthesis of nanoparticles, biomedical application including 
gene delivery, drug entrapment/release, soil remediation, enhanced oil recovery, and 
antimicrobial activity as effective emulsifiers, dispersants, bactericidal agents, antifoaming 
agents, and detergents. [92, 101, 102]. The extremely low CMC of GSs means reduced 
toxicity in vivo as well as minimized cost since less surfactants is required [7, 55]. 
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Furthermore, as the GSs provide a higher positive charge per mass ratio than the monomeric 
counterparts, a relatively lower amount is sufficient to rapidly complex a given aliquot of 
DNA in a more compact fashion leading to smaller sized nanoparticles (a critical factor for 
cellular uptake and intracellular trafficking) [6]. 
The general structure of gemini surfactants is shown in Scheme-1.1 [7, 103]. The long 
hydrocarbon chain of the GS tends to increase the surface activity. Increasing the 
hydrophobicity may make the molecule water-insoluble, whereas increasing the 
hydrophilicity of the head group may impart water solubility. Hydrophilic groups in the 
spacer also increase the aqueous solubility. An increase in carbon number in the nonpolar 
chain increases both lipophilicity and surface activity [6, 89]. Hence, the molecular structure 
of the GSs provides significant opportunities to vary their structure compared to their 
monomeric counterparts by independently modifying the spacer, one or both head-groups, 
and one or both hydrophobic tails or the associated counterions to obtain an extremely wide 
range of compounds. This ultimately opens a new horizon to fine tune the self-aggregation of 
GSs based liposomes to obtain a better control on biological activity (DNA delivery) and 
other solution properties [7, 55]. 
Owing to their remarkable properties, considerable attempt has been made for the 
design and synthesis of novel GSs of various categories to study the relationship between 
their molecular structures and their aggregation morphologies in aqueous solution [104]. In 
comparison of the monomeric counterparts of the GSs, the spacer group has been known to 
strongly affect the self-assembly of gemini surfactants in aqueous solution, and thus 
considered as a unique component in gemini structure. So far, the various gemini surfactants 
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containing different spacers, for example, a flexible hydrophilic, flexible hydrophobic, or 
rigid hydrophobic, have been investigated [104, 105]. 
 
 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
C    D 
 
 
 
 
 
 
Scheme-1.1: (A) General structure of a conventional and gemini surfactant (without the 
associated counterions); (B) Structure of m-s-m GSs (C) Model representing simple lipids, 
and (D) Gemini lipids {A & B – adapted from [7]}. 
 
 
Numerous studies reveled that gemini surfactants are able to compact DNA 
efficiently when the spacer length s is <4 or >10. Besides, the spacer lengths correspond to 
CHAPTER-1: INTRODUCTION 
24 
 
conditions where cylindrical micelles (s < 4) or bilayer structures (s > 12) are known to form. 
Conversely, intermediate length spacers in gemini were found to be less effective [7, 106, 
107]. Now, in case of hydrophobic tail lengths, a general rule for ionic surfactants is that, in 
aqueous medium, the CMC decreases as the number of carbon atoms in the hydrophobic 
group increases and it is halved by the addition of one methylene group to a straight-chain 
hydrophobic group attached to a single terminal hydrophilic group. Due to the coiling of the 
long chains in water, when the number of carbon atoms in a straight-chain hydrophobic 
group exceeds 16, the CMC no longer decreases so rapidly with increase in the length of the 
chain, and when the chain exceeds 18 carbons it may remain substantially unchanged with 
further increase in the chain length [108, 109].  
 
 
1.3.1 Gemini Surfactants (GSs) for DNA transfection in GT  
Compaction of DNA by gemini surfactants is affected by both the nature of the head 
group (effective head group area, valence) and the length and saturation of the hydrophobic 
tail. The optimal structure(s) formed by self-aggregation of these surfactants can be predicted 
by the surfactant packing parameter or critical packing parameter, CPP or P (Figure-1.7), 
which can be calculated by the following equation –  
 
 P = v / (a
0*
l)        1.1 
 
where v = volume of alkyl tail, l = length of alkyl tail, and a
0 
= surface area occupied by the 
head-group. The P value indicates the preferred curvature of the structure and a value of 0.3 
is typical for spherical micelle organization (highly curved), whereas P = 1 represents planar 
bilayer formation and P > 1 applies to inverted micelles [7, 108, 110]. 
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Figure-1.7: Packing parameter showing different morphologies of amphiphilic aggregates 
defined by Israelachvili (adapted from [83]). 
 
 
 
When binding with negatively charged DNA the packing parameter for vesicle 
systems (P > 0.5) is larger than that of micelle systems (P < 0.5), and therefore it is easier for 
a vesicle system to form non-lamellar structures such as inverted hexagonal and cubic 
morphologies (P≥1). When lipoplexes interact with anionic lipids it makes DNA release 
easier from the lipoplexes and the low curvature phases (inverted hexagonal and cubic 
morphologies) are the controlling factors in lipid-mediated delivery [110]. 
Electrostatic forces along with attractive hydrophobic interactions, hydrophobic 
hydration, and the repulsive forces existing between DNA – DNA and surfactant – surfactant 
molecules trigger the formation of DNA – surfactant complexes for gene delivery [93, 110]. 
These interactions change the shape and size of macromolecular DNA without the loss of 
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therapeutic (biological) properties of the genetic material, into various morphological shapes 
that are readily taken up by cells [103].  
As mentioned previously, the cationic gemini surfactants effectively complex and 
condense the DNA and provide an overall positive charge to the transfection complex 
(depending on the charge ratio used) to allow interaction with the negatively charged cell 
membrane. Studies on transfection efficiencies of gemini-DNA complexes with respect to 
charge ratio suggested that transfection was optimum with excess cationic gemini where the 
gemini/DNA charge ratio is approximately 10 [110].  After the rapid uptake of the DNA-
vector complexes by the cell, it is thought that the transfection complexes will escape the 
endosome by their ability to form different morphological shapes such as inverse hexagonal 
(H
C
II) or cubic phases (Pn3m). Gemini surfactants that are capable of forming vesicle 
(lamellar) structures in aqueous solution have improved transfection efficiencies than those 
with micelle structures due to higher surfactant packing parameter, P value [110].  
The total volume of hydrophobic tails of typical cationic surfactant molecules 
increase faster than that of the head group areas, because of the existing electrostatic 
attraction between the positive head groups and other oppositely charged moieties (such as 
counterions). Lamellar lipoplexes generally bind with anionic lipids of cellular membranes 
and increase the packing parameter of the cationic surfactants which allow the formation of 
inverted hexagonal or cubic structures [110]. However, these non-lamellar structures are not 
favorable for binding DNA; instead they are favorable for releasing DNA after cellular 
internalization.  
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1.3.1.1 Role of DOPE lipid in gemini mediated DNA transfection for GTs 
To achieve better transfection efficiencies 1,2-dioleoyl-sn-glycero-3-phosphatidyl 
ethanolyamine, DOPE (Figure-1.3), an important neutral helper lipid is often added to gemini 
surfactant-based gene delivery formulations to facilitate the endosomal escape – a crucial 
barrier for GT [110].  
Endosomal escape by DOPE mediated lipoplexes has shown that the escape 
mechanism is independent of membrane charge density. Inside the cell membrane, generally 
when the endosome matures to lysosome, its pH reduces to acidic condition. This drop in pH 
triggers lamellar (L
C
α) to inverted hexagonal phase (H
C
II) transitions of DOPE lipids in the 
lipoplexes. The negative curvature of this inverted hexagonal lipoplexes results in an 
elastically frustrated state with the outer lipid monolayer, possessing a positive curvature, 
that surrounds the lipoplexes; this establishes the driving force for rapid fusion with cell and 
endosomal membranes [111, 112] (Figure-1.8), hence the DOPE is sometimes termed as 
“fusogenic lipids”. The ability of DOPE mediated lipoplexes to adopt inverted hexagonal 
phase structures for rapid fusion and endosomal escape is a significant contributing factor 
[110] to higher transfection efficiency when compared to lipoplexes with lamellar phase 
structures. 
Studies have shown that the presence of the helper lipid DOPE increased the 
transfection efficiency about 10 fold [103, 113]. Addition of pure DOPE causes formation of 
mixed aggregates with higher (greater than unity) packing parameter value of the systems; 
shifting micelle systems towards vesicles, and vesicle systems toward the inverted hexagonal 
or even cubic phase. In addition, DOPE has a positive role to increase the fluidity of cellular 
membranes and thus facilitates the penetration of genetic materials into the cell. Furthermore, 
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it also helps in disruption of the endosomal membrane at the endosomal escape phase leading 
to increased transfection efficiency [110].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1.8: Schematic illustration of endosomal escape of fusogenic DOPE mediating 
lipoplexes. Consistent reduction in pH trigger lamellar to inverted hexagonal phase 
transitions (A), prompting an elastically frustrated state that drives rapid fusion with 
endosomal membrane and endosomal escape (B) (reused from [79] through the permission of 
author).  
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1.3.2 Effects of Counterions 
1.3.2.1 Counterion effects on gemini surfactant aggregation 
Many attempts have been made to investigate the effect of salts on micelle formation 
in light of the Hofmeister (lyotropic) series and other numerous counterions 
(organic/inorganic, monoatomic/polyatomic, nucleotides, peptides etc.) [84, 114-122]. 
Unfortunately, despite the structural diversity of gemini surfactants, only a few studies have 
focused on the effect of the gemini surfactant counterions  on the micellization properties  
other than bromide or chloride [123]. As the specific properties (solubility, CMC, 
aggregation behaviour, richer morphology, and other solution properties) [97, 124] of gemini 
varies depending on the associated counterions (along with their chain lengths and spacer 
groups), the focus of this section will be to discuss those solutions properties of gemini 
surfactants with different inorganic and organic counterions. 
The effects of salts on aggregation behaviors of ionic surfactants in aqueous solutions 
are vital to many applications for detergency and emulsification in industry as well as in 
biotechnological fields [115]. Oda et al. (2010) investigated and analyzed the effect of 
counterions to probe the principal ionic effects influencing the micellization behavior of the 
dimeric 14-2-14 gemini surfactants [123]. The critical micelle concentration (CMC), 
ionization degree of micelle (α), free energy of micellization (ΔGM), and aggregation 
numbers (N) of the gemini surfactant (14 – 2 – 14) were used to demonstrate the effect of 
different anion properties. In their study, among various groups of counterions (Figure-1.9), 
they include nitrate (NO3
-
), iodide (I
-
), bromide (Br
-
), chloride (Cl
-
), fluoride (F
-
), dihydro-
phosphate (PH
-
) and acetate (C2
-) ions within the “small counterions group”; and the 
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methoxyacetate (MeOAc), lactate (LACT), trifluoroacetate (TFA), diphenate (DIPH), 
sulphate (SO4
2-
) and tartrate (TART) ions were included in the “orphan group”.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1.9: Various groups of counterions in the study of Oda et.al (reused with permission 
from [123]. Copyright [2010], American Chemical Society). 
 
 
The hydrophilicity of the anions is the primary factor determining micellization and is 
inversely related to micellization process. The higher hydrophilicity of a counterions leads to 
high CMCs of the GS (Figure-1.10: Table-1) [123]. Studies showed that the smaller 
counterion groups generally follow the Hofmeister series in terms of CMC: the CMC of the 
GS 14-2-14.X
-
 was found to increase according to the Hofmeister series: I < NO3
-
 ∼ Br-< Cl- 
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< F
-
 ∼ C2
-
 < PH
-
. Among the halide ions of this group, the most polarizable and least 
hydrated iodide (I
-) ion has a large negative energy transfer value (ΔGHB) indicating that it is 
a very chaotropic anion which destroys the structure of water in its vicinity leading to the 
lowest CMC value. 
 
 
 
 
 
 
 
 
 
Figure-1.10: Table-1 describing the CMC and other parameters of 14-2-14 gemini associated 
with the Hofmeister series counterions in the head group (reused with permission from [123]. 
Copyright [2010], American Chemical Society). 
 
 
 
Although two other halides Br
-
 and Cl
-
 have intermediate properties, the fluoride (F
-
) 
ion displays opposite properties compared to iodide (I
-
) ion since it is the smallest anion, the 
least polarizable, the most hydrated, and the most Kosmotropic. Overall, for monatomic 
anions, the hydration number is directly related to the hydrophilicity: the more hydrophilic 
anions have smaller polarizability and higher hydration number leading to higher CMC 
values. On the other hand, due to entropic reasons the micellization is disfavored for large 
and polyatomic anions with lower hydration number but with similar hydrophilicity of the 
monoatomic anions (Figure-1.11: Table-2 & Table-3) [123].  
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Figure-1.11: Table-2 & Table-3 describing the various solution properties of 14-2-14 gemini 
with various organic and polyatomic counterions in the head group (modified from [123]). 
 
 
 
In case of aliphatic carboxylates counterions, the CMC of the GS was found to 
decrease with increasing chain length (increasing hydrophobicity) of the carboxylate ions 
except for the acetate ion (Figure-1.12). But in case of aromatic carboxylates, the CMC of the 
gemini increases with higher hydrophobic property of the aromatic carboxylate counterions 
although the solubility is very low. For the same reasons as described above for the 
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Hofmeister series ions, among the orphan counterions, the CMC was found to be lowest for 
the tartrate ion and highest for the methoxy acetate [115, 123]. In summary, the counterions 
has a marked influence on both micellization and aggregation of the GS and these effects of 
counterions depends on the complex interplay between hydrophobicity of anions and other 
ion properties such as counterion hydration, interfacial packing of ions, and ionic 
morphology [123]. 
 
 
 
 
 
 
 
 
Figure-1.12: CMC of the 14-2-14 with aliphatic carboxylate counterions at 30
0
C (reused 
with permission from [123]. Copyright [2010], American Chemical Society). 
 
 
1.3.2.2 Counterion effect of amphiphiles on transfection 
Until recently, there were no investigations done on the effects of counterions of 
gemini surfactants on in vitro transfection efficiencies. Thus, due to lack of published papers 
on the effect of counterions on transfection, this section will discuss the effect of counterions 
on transfection done through cationic lipids, or cationic polymers in cancer cell lines.   
The effect of counterions (chloride, bromide, methyl sulfate, bisulfate, and triflate) on 
the in vitro transfection of the DOTAP emulsion system was investigated in one of the study 
CHAPTER-1: INTRODUCTION 
34 
 
by Young et.al [125]. From this study it was revealed that the counterions associated with the 
lipid head groups significantly affect the binding of the DNA and carrier system. Here, the 
bisulfate (H2SO4
–
) and triflate counterions (trifluoromethanesulfonate, CF3SO3
–
) promoted 
significant water dislocations and re-structuring via different orientations, and this extensive 
water organization are mainly responsible for cationic lipid head group dehydration [125]. 
According to thermodynamic rules, generally cationic lipids’ head group dehydration 
promotes greater amphiphile packing, leading to smaller aggregates that are destabilized 
through charged head group repulsions. While increased electrostatic repulsions give rise to 
metastable particles whose free energies are reduced upon DNA-induced amphiphile re-
organization.  
The methyl sulfate counterions encouraged the lowest levels of transfection activity 
(Figure-1.13), presumably due to the stronger electrostatic interaction of sulfate di-anion that 
supersedes the predicted Hofmeister series of neutral salts. The halogens were more closely 
associated with the alkyl ammonium head group (charge shielding), in the order of chloride 
to bromide. An increase in charge shielding leads to water exclusion and closer inter-chain 
packing, consequently leading to an average increase in the transfection activity from 
chloride to bromide (Figure-1.13) [125, 126].  
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Figure-1.13: Effect of DOTAP with counterions for in vitro transfection in COS-1 cell lines 
(reused with permission from [125]. Copyright [2001], Springer). 
 
 
From the literature review, it is evident that, the nature and the type of the counterion 
associated with the head group of an amphiphile has an important influence on the 
conformation of the amphiphile in solution, and also on the size and the stability of the 
complexes with DNA [127-129]. In 2004, Saaida et al. used chloride, acetate and 
lactobionate counterions for the poly-norbornene based cationic amphiphile (Figure-1.14) in 
their work, where the DNA is not only complexed by electrostatic interactions, but also by 
the hydrophobic effect and packing of the poly-norbornene based polymeric units (cationic) 
[130]. It was reported that the polymer with the chloride counterion is a fully quarternized 
polymer and they can form only stretched chains within the polymer seen from TEM images. 
Chloride is a counterion strongly bonded to the ammonium group, leading to a shielding of 
the electrostatics repulsions between the units and the formation of large aggregates. 
Consequently, the interaction/complexation with DNA involves essentially the electrostatic 
CHAPTER-1: INTRODUCTION 
36 
 
interactions and gives rise to weakly complexed aggregates with large toroidal or spherical 
morphologies, which can be easily displaced by the heparin and degraded by DNase I, except 
only at high NH3
+
/PO4
−
 ratios (>2) (Figure-1.15) [130].  
 
 
 
 
 
 
 
 
Figure-1.14: Poly-norbornene based cationic amphiphiles based on different counterions (X
–
), where X
– 
= Chloride, Acetate, and Lactobionate anions respectively (reused with 
permission from [130]. Copyright [2004], Elsevier). 
 
 
On the other hand, with acetate counterions (CH3COO 
–
), the poly-norbornene is able 
to produce latex particles with packed cores formed by the non-quarternized polymeric units, 
surrounded by hydrophilic moieties (ammoniums) [128]. The acetate counterion is loosely 
bonded to the ammonium group leading to the strengthening of the electrostatic repulsions 
between the ammoniums, but at the same time this effect increased the hydrophobic 
interactions between the norbornene units. In this case, the interactions with DNA are both 
electrostatic and hydrophobic, strengthening the stability of the complexes leading to only 
small spherical aggregates; which in turn affect the in vitro transfection efficiency (Figure-
1.15). Also, this high affinity and strong interactions explain why this complex is not easily 
displaced by heparin [130]. 
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Lastly, the lactobionate counterion (lactobionic acid, C12H22O12) is a sugar, weakly 
bonded to the ammonium group, and promotes water organization by a kosmotropic effect. 
For this polymer, electron microscopy image showed that these latex particles consisted of a 
packed core, formed by the non-quarternized norbornane units, surrounded by the methylene-
ammonium units and a shell of hydrated lactobionate counterions [130]. Here, the 
kosmotropic effect leads to dehydration of the ammonium group increasing their repulsion 
and promoting a greater hydrophobic packing of the norbornane units. The conjunction of 
these two effects gives rise to very small (with a diameter of around 10–20 nm) but 
metastable particles. Finally, the metastable nature of these complexes explains that the DNA 
is easily displaced by the heparin [130]. Thus, the transfection efficiency for all the polymers 
increased with the NH3
+
/PO4
−
 ratio (Figure-1.15), possibly due to an increasing interaction of 
the different polymers/DNA complexes with the cell surface, and also due to the positive 
charge on the complexes, which partly depends on the nature & type of the counterions.  
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Figure-1.15: Transfection efficiencies of methylene-ammonium poly-norbornene polymers 
into CHO cell lines. The cells were incubated with poly-norbornene polymers/DNA complex 
containing 5 μg of plasmid DNA and poly-norbornene polymers at different NH3
+
/PO4
−
 
ratios. Cells were harvested and GFP activity determined 48 hour after transfection (reused 
with permission from [130]. Copyright [2004], Elsevier). 
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1.3.3 Selected counterions of the gemini surfactants for this project 
In this work we present a study of 16-2-16 gemini surfactants coupled with 8 different 
counterions (Chart-1.1) classified into three general groups: (1) small inorganic counterions, 
which are mainly taken from the Hofmeister series, (2) organic hydroxy-alkyl-di-carboxylate 
counterions, in which the hydrophilicity of the anion can be modified by inserting hydroxyl 
group, while keeping the same carbon length and net charge, and (3) the four nucleotide 
mono-phosphate counterions where ribose sugar and heterocyclic rings (purine/pyrimidine) 
are present in their structures.  The following figure (Figure-1.16) shows the association of 
monovalent and divalent counterions with one 16 – 2 – 16 GS molecule. 
 
 
 
 
 
 
 
 
 
     Gemini-UMP     Gemini-Tartrate          Gemini-Malate 
 
Figure-1.16: Structure of Gemini-UMP, Gemini-tartrate, and Gemini-malate (reused with 
permission from [121, 131] respectively. Copyright [2005], Elsevier and copyright [1998], 
John Wiley and Sons respectively). 
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Chart-1.1: The counterions (X 
–
) associated with 16-2-16 series of gemini: 16-2-16.2X 
–
 
Group-1: Small counterions from Hofmeister series 
Br 
–
 Cl 
–
 
Bromide 
 
Chloride 
 
Group-2: Hydroxy-di-carboxylates (aliphatic, organic) 
 
 
 
 
 
 
 
 
 
 
Malate 
 
Tartrate 
 
Group-3: Nucleotide mono phosphates, NMPs (organic) 
 
 
 
 
 
 
 
 
 
 
 
Adenosine 5´mono phosphate (AMP) Uridine 5´mono phosphate (UMP) 
  
 
 
 
 
 
 
 
 
 
 
 
Guanosine 5´mono phosphate (GMP) Cytidine 5´mono phosphate (CMP) 
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2. Objectives & Hypothesis 
2.1 Overview of the project 
Success of GT relies on having efficient vectors for the transfer and expression of the 
genetic material at the desired location in the living organism. As discussed earlier, 
exploitation of the inherent ability of viruses to infect cells has produced the most efficient 
delivery vectors in gene therapy, but limitations in the safety of viral vectors restrict the 
application of this method. These limitations have motivated our group in the development of 
an effective non-viral vector, which uses synthetic, self-assembling gemini surfactants to 
deliver the DNA. Our goal is to develop new non-viral systems with high transfection 
efficiencies through the modifications of different counterions of gemini surfactants. As 
previously mentioned (section 1.3), earlier studies have focused on the effect of variations in 
the chemical structure of the surfactant itself. It has been previously established that 
significant modification in the shape of nanoparticles, formed from gemini surfactants, can 
be achieved through variations in the counterions.  We believe that appropriate selection of 
counterion will allow for better control of nanoparticle size/shape in our non-viral gene 
therapy vectors. 
 This work will focus on the characterization of cationic gemini nanoparticles 
formulated with GSs associated with hydrophilic/hydrophobic anions (mono-atomic or 
organic) and will investigate the effect of counterions on transfection efficiency by 
modifying micellization process of DNA-GS complexes. The study will also outline the 
effects of counterions on micellization of GS in terms of interaction between hydrophobicity 
of the anions and other ion properties (hydration number, polarizability, ionic morphology 
etc.).  
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Methods that will be used to study the self-aggregation, solution properties, and 
interaction behavior of DNA with GS having different anions are: Tensiometry, 
Conductometry, Krafft Temperature & Solubility measurements, Densitometry, pH 
measurements, Viscometry, Dynamic Light Scattering (DLS), Laser Doppler Velocimetry 
(LDV), and lastly in vitro transfection in human epithelial ovarian cancer cell lines 
(OVCAR-3, ATCC). The recombinant plasmid DNA (pDNA), pNN9 (a circular covalently 
closed, double stranded helix DNA molecule encoding for an enhanced green fluorescence 
protein gene, EGFP) will be extracted from Escherichia coli and can be used in the 
nanoparticle formulations for all in vitro transfection assays. Transfected cells will express 
EGFP once the pDNA is transcribed in the nucleus of the cancer cells, and the resultant 
messenger ribonucleic acid (mRNA) will be translated. The possible outcome will be the 
development of less toxic non-viral DNA transfection agent based on different counterions of 
the gemini surfactants with improved transfection efficiency for human ovarian cancer cells.  
 
2.2 Hypothesis statement 
Nanoparticles formulated from gemini surfactants having different counterions will 
enhance the DNA transfection efficiencies for epithelial ovarian cancer cells. 
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2.3. Objectives: short-term goals 
The specific objectives of this project include:  
1. Syntheses of all the GSs with selected counterions 
2. Physiochemical characterization of GSs and gemini nanoparticles by studying: 
a. Tensiometry 
b. Conductometry 
c. Krafft Temperature measurements 
d. Densitometry & pH measurements 
e. Viscometry 
f. Zeta potential (LDV) and Particle size (DLS) [for nanoparticles]. 
 
2.4. Objectives: long-term goals 
Investigation of the in-vitro transfection efficiency, in OVCAR-3 examining:  
a. Effect of concentration of gemini 
b. Effect of different counterions associated with the gemini 
c. Effect of charge ratio of surfactant to DNA 
d. Effect of helper lipid along with gemini  
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3. Materials & Methods 
3.1 Materials 
3.1.1 Materials for GS syntheses 
The raw materials used for the synthesis of gemini surfactants (GSs) were 1-
bromohexadecane (99.5 %, Fisher Scientific), 1-chlorohexadecane (99.5 %, Fisher 
Scientific), N,N,N′,N′-tetramethylethane-1,2-diamine, TMEDA (99%, Fisher Scientific), L-(–
) malic Acid (98%, Sigma-Aldrich), L-(+) tartaric Acid (98%, Sigma-Aldrich), silver Acetate 
(99%, Fisher Scientific), silver carbonate (98%, Fisher Scientific), adenosine 5′-
monophosphate, AMP (99.8%, mono-hydrate & acid form, Sigma Aldrich), cytidine 5′-
monophosphate, CMP (99.9%, acid form, Sigma Aldrich), uridine 5′-monophosphate, UMP 
(99.9%, acid form, Sigma Aldrich), and guanosine 5′-monophosphate, GMP (99.8%, acid 
form, Fisher Scientific). These materials were purchased from the specified companies and 
used directly without any further purification. All solvents used in the syntheses of GS were 
of HPLC grade (99.99%) and were purchased from Fisher Scientific, USA. Deuterated 
chloroform (chloroform-D, 99.8 atom % D), DMSO-d6 (99.9 atom % D), and deuterated 
water (heavy water, 99.9 atom % D) were purchased from Sigma Aldrich (USA) and directly 
used for 
1
H NMR analysis (AVANCE 300 MHz, BRUKER, USA) of raw materials (where 
applicable) and synthesized GSs. For all experimental analyses, GS solutions were prepared 
by using fresh ultrapure Milli Q water (Filtered through 0.22 μm Millipak 4.0 Filter, TOC 
(Total Organic Carbon) = 1 ppb, Specific resistance = 18.2 MΩ.cm @ 250C) dispensed from 
Gradient A-10 Milli Q water system (Millipore, Canada) as required. 
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3.1.2 Materials for in vitro transfection 
3.1.2.1 Chemicals / Reagents for transfection 
DOPE [1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine] solution 
(99%), 25 mg/mL in CHCl3 (C41H78NO8P, M.W.  = 744.05 g/mole) was purchased from 
Avanti Polar Lipids Inc. (USA) and stored at – 20oC. (±) α-Tocopherol (95%, synthetic, 
ACROS Organics™) [F.W. =430.72, S.G. = 0.95] used as membrane stabilizer for DOPE 
liposome preparation, was purchased from Fisher Scientific (USA) and used as received. 
The following materials were also purchased from Fisher Scientific (USA):  
 DPBS (Dulbecco's Phosphate-Buffered Saline, 1 X, without Ca2+ & Mg2+, pH 7.2) 
 RPMI 1640 1X with L-Glutamine + Phenol Red 
 Fetal Bovine Serum [FBS, 20% (v/v)] 
 Trypsin [0.25% (w/v) Trypsin (1X) + 0.53mM EDTA; w/o Ca2+ & Mg2+] solution 
 TrypLE™ Express [animal origin free (AOF), recombinant enzyme] solution 
 Penicillin/Streptomycin antibiotics (10,000U/mL Penicillin, 10,000μg/mL 
Streptomycin in 0.85% NaCl) 
 Trypan Blue 0.4% (w/v, pH = 7.5 ± 0.5) in DPBS, and  
 Propidium Iodide Solution in DPBS 
 
Opti-MEM
®
 I (1X) Reduced-Serum Medium w/o Phenol Red, and Lipofectamine
TM
 2000, 1 
mg/mL was purchased from Gibco
®
 and Invitrogen
TM
, Life technologies (NY, USA) 
respectively. Bovine Pancreas Insulin (10 mg/mL insulin in 25 mM HEPES, pH 8.2) solution 
was purchased from Sigma Aldrich (USA). All these materials mentioned in this section 
were used as received without any further purification.  
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3.1.2.2 pDNA  
 The recombinant plasmid DNA pNN9 (Figure-3.1) was a generous gift from Dr. 
Roderick Slavcev (School of pharmacy, University of Waterloo). After subsequent 
amplification, extraction, and confirmation of the extracted DNA by gel electrophoresis and 
size determination, these pNN9 plasmids were used for all size and zeta potential 
characterizations and for all transfection assays. K-12 strains of Escherichia coli (a Gram-
negative, anaerobic, rod-shaped bacterium) were used in the generation of the recombinant 
cell constructs and JM109 strains of the same bacterium were employed as hosts for plasmid 
amplification for extraction. For the extraction of pNN9 plasmids intended for size & zeta 
potential characterization, centrifugation protocol of the E.Z.N.A.
®
 Plasmid DNA Maxi Kit 
(OMEGA bio-tek, Georgia, USA) was used. To eliminate the resulting endotoxins, on the 
other hand, E.Z.N.A.
®
 Endo-Free Plasmid DNA Maxi Kit was used for extraction of the 
plasmids that are intended to be used for all transfection assays.   
 
 
 
 
 
 
 
 
 
Figure 3.1: The pDNA vector (pNN9) used in this project. This 5.6 kb pDNA vector (pNN9) 
possesses two Super Sequences (SS, a multipurpose target site) flanking the eukaryotic 
expression cassette. SV40 enhancer sequences serve as DNA-targeting sequences (DTS) for 
improved nuclear entry during gene delivery. The EGFP (enhanced green fluorescence 
protein) gene is the gene of interest used for confirmation of successful transfection (reused 
with permission of BioMed Central from [132] through the Creative Commons Attribution 
License).   
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3.1.2.3 Cell Line 
The adherent cell line that was used for transfection assay in this project is human 
epithelial ovarian cancer (NIH:OVCAR-3) cell line (HTB161™) from ATCC® (Manassas, 
VA; USA) which is androgen, estrogen, and progesterone receptor positive.  
 
3.2 Methods 
3.2.1 Synthesis of 16-2-16 series of GSs [C16H33(CH3)2-N
+
-(CH2)2-N
+
-(CH3)2C16H33].2X
–  
3.2.1.1 Synthesis of 16-2-16 with bromide and chloride counterions 
The gemini surfactants with bromide and chloride counterions were synthesized 
according to the method of Menger and Littau with minor modification (Scheme-3.1) [90, 
133-135]. An excess (10 – 50%) of two molar equivalents of the appropriate hexadecyl-
halide, C16H33-X
–
 (X
–
 = bromide, chloride) and one molar equivalent of N,N,N′,N′-
tetramethylethane-1,2-diamine (TMEDA) in acetonitrile was refluxed with continuous 
stirring for 6 – 12 days, in order to obtain one molar equivalent of corresponding 16-2-16 
gemini-halide (halide = bromide, chloride). After reaction, the solvent was removed via 
rotary evaporation with the resulting product being dissolved in a minimum volume of 
chloroform (CHCl3) : methanol (CH3OH) (9 : 1, v/v) and recrystallized with excess acetone. 
Recrystallization was repeated 2 – 3 times [134, 135] in order to obtain pure (confirmed by 
1
H NMR analysis and Tensiometry) gemini surfactants. The white crystals of gemini 
surfactant were collected via vacuum filtration through grade-41 filter paper (Whatman
TM
 
routine quantitative ashless filter paper, Fisher Scientific, USA), and then dried under 
vacuum at a temperature of 35 – 400C for 5 – 6 days until a constant weight was attained. 
The chemical structure and purity of the gemini surfactants was verified by 
1
H-NMR (in 
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CDCl3). The 16-2-16-bromide was used as the parent compound for the syntheses of the 
remaining categories of GSs.  
 
                                            CH3CN 
    2 C16H33-X
–
   +   TMEDA                      C16H33N
+
(CH3)2– (CH2)2–N
+
(CH3)2C16H33 .2X
–
 
      (2 molar         (1 molar        reflux    (1 molar 
      equivalents)     equivalent)     equivalent) 
 
10 - 50% excess   
                     
Scheme-3.1: Synthesis reaction for the preparation of 16-2-16-halides 
 
3.2.1.2 Synthesis of 16-2-16 with tartrate and malate counterions 
The tartrate and malate salt of the 16-2-16 surfactant were prepared according to 
Scheme 3.2.  
i)                 
 
 
ii)  
 
 
 
Where, R = Hexadecyl Group (C16H33 –); HX = Malic Acid / Tartaric Acid 
 
Scheme-3.2: Synthesis reactions for the preparation of 16-2-16-malate and 16-2-16-tartrate 
 
A solution of the silver salt of tartaric or malic acid in methanol was prepared 
(scheme-3.2, reaction-i) freshly by adding silver carbonate Ag2CO3 (10% excess) to the 
stoichiometric amounts of tartaric or malic acid solution (in CH3OH) followed by constant 
vigorous stirring at 50
0
C under slight vacuum to remove carbon dioxide for 90 minutes. A 
methanol solution of the 16-2-16.2Br
–
 surfactant (stoichiometric amount) was added to the 
freshly prepared silver tartrate or malate solution, and the mixture was stirred for 3 hours at 
50
0
C. A black precipitate of the silver bromide (Ag-Br) was observed within 3 hours, 
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indicating complete exchange of counterions. Celite was added and mixed via constant 
stirring for 30 minutes. After cooling to RT, the solution was filtrated over Celite, ensuring 
the complete removal of Ag-Br. The filtrate was rotary evaporated to remove the methanol 
solvent leaving a liquid that was dissolved in a chloroform (CHCl3) : methanol (CH3OH) (9 : 
1, v/v) mixture. The resulting gemini-tartrate or gemini-malate surfactant was precipitated 
with excess acetone or ethyl acetate [117, 136]. The surfactants were recrystallized from the 
same solvent system three times to ensure purity. The off white crystals were collected by 
vacuum filtration dried under vacuum at 35 – 400C until constant weight was attained. 
Structure and purity of the gemini-tartrate and gemini-malate surfactants was verified via 
1
H 
NMR (in D2O).  
 
3.2.1.3 Synthesis of 16-2-16 with nucleotide mono phosphate (NMP) counterions 
16-2-16.2NMP gemini surfactants were prepared in two steps: i) exchange of bromide 
ions with acetate (Scheme-3.3), followed by ii) exchange of acetate counterions with the 
corresponding nucleic acids (Scheme-3.4). 
 
i) Gemini (16-2-16) bromide-acetate exchange: 
C16H33N
+
(CH3)2– (CH2)2–N
+
(CH3)2C16H33 .2Br 
-   
+  2.CH3-COO
-– Ag+    
    MeOH                 
C16H33N
+
(CH3)2– (CH2)2–N
+
(CH3)2C16H33 .2Ac  + 2 AgBr 
 
Scheme-3.3: Ion exchange reactions for 16-2-16-bromide to 16-2-16-acetate 
 
To 100 mL of 16-2-16-bromide solution (in MeOH), silver acetate (Ag-Ac) (10% 
excess) was added followed by constant stirring at 55 – 600C for 4 hours. Silver bromide 
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(AgBr) precipitate appeared within 4 hours, indicating complete exchange of counterion. The 
solution was filtrated over Celite, and the remaining filtrate was rotary evaporated to remove 
the solvent. The resulting dense liquid was dissolved in chloroform (CHCl3) : methanol 
(CH3OH) (9 : 1, v/v) mixture, and the gemini-acetate powder was obtained by precipitating 
with excess acetone (or ethyl acetate) followed by 3 recrystallizations in the same solvent 
system [137]. The off white crystals were collected by vacuum filtration, dried under vacuum 
at 35 – 400C until constant weight was attained. Structure and purity of the gemini-acetate 
surfactant was verified via 
1
H NMR (in D2O). 
 
ii) Gemini 16-2-16.2Ac to 16-2-16-nucleotides: 
 
 
         +  2 CH3–COOH 
                                                                    H2O 
 
 
Where, R = Hexadecyl Group (C16H33 –); HX = Nucleotide Mono Phosphates, NMPs (AMP, GMP, CMP, UMP)  
 
Scheme-3.4: Ion exchange reactions for 16-2-16-acetate to 16-2-16-NMP 
 
Approximately 50 mL of aqueous solution of the gemini-acetate was added to an 
aqueous solution (80–100 mL) of the desired nucleotide mono phosphate, NMP (10% 
excess) followed by constant stirring for 3 – 4 hours at 45 – 500C. Upon completion, the 
mixture was cooled to room temperature and then allowed to freeze at –800C overnight 
before lyophilization. The frozen GS-NMP samples were lyophilized for 4–6 days with a 
FreeZone® 2.5 L Freeze Dry System (Labconco Corporation; Kansas City, Missouri) at an 
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operating temperature of –860C. Consecutive lyophilisation and dissolution in water were 
repeated until the total evaporation of acetic acid occurred (confirmed by 
1
H NMR) [137].  
 
3.2.2 
1
H NMR characterization  
All 
1
H NMR measurements were carried out at 25.0 ± 0.1
0
C on a Bruker Avance 
NMR spectrometer operating at 300 MHz with the field strength of 7.0 Tesla. D2O and 
CD3OD (99.9 atom % D) were used to prepare stock solutions (7-10 mg/mL) of the 
synthesized surfactants for 
1
H NMR study. The peaks were referenced with respect to 
tertamethylsilane, TMS (δ = 0.00 ppm) when CD3OD was used as a solvent and to 4,4-
dimethyl-4-silapentane-1-sulfonic acid, DSS (δ = 0.00 ppm) when D2O and/or DMSO was 
used as a solvent. In all NMR experiments, the number of scans (16 on average) was adjusted 
to achieve good signal-to-noise, and was recorded with a two seconds relaxation delay in a 
digital resolution of 0.04 Hz/data point at a flip angle of 30
0
 of the pulse program. The 
following notation was used for the 
1
HNMR splitting patterns: singlet (s), doublet (d), triplet 
(t), multiplet (m), and double doublet (dd).  
 
3.2.3 Measurement of CMC 
Critical micelle concentrations (CMC) of all the synthesized GSs were determined 
using surface tension and specific conductance measurement methods.  
 
3.2.3.1 Surface Tension measurement 
Surface tension measurements were carried out using the du Noüy ring method [84, 
94, 105, 138] on a Lauda TE3 automated Tensiometer (Lauda, Germany) equipped with a 
Platinum-Iridium (Pt–Ir) alloy du Noüy ring with a circumference of 6.001 cm (radius = 
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0.955 cm). The ring was thoroughly cleaned and flame dried before each experiment. 
Concentrated stock solutions (0.3 mM, and 0.01 mM) of the surfactant of interest were added 
to 50 mL of freshly dispensed Milli-Q water (kept within the Simax 80 vessel, Fisher 
Scientific, USA) using a model 765 Dosimat auto-titrator (Metrohm, USA) and surface 
tension readings were taken after thorough mixing and temperature equilibration. The 
measured surface tension values were automatically corrected according to the procedure of 
Harkins and Jordan [139, 140] using the instrument software. All measurements were carried 
out in replicates with a minimum of five successive measurements having a standard 
deviation that did not exceed 0.10 mN/m. Temperature was maintained at a constant value 
(25 ± 0.05
0
C) using a Lauda Ecoline RE 304 (Lauda, Germany) circulating water bath. All 
CMC determinations were carried out in duplicate for each of the gemini surfactants studied. 
     
3.2.3.2 Conductivity measurements: 
Electrical conductivity was used to determine the critical micelle concentration 
(CMC) and the degree of micelle ionization (α) of the GSs. Since the conductivity is strongly 
influenced by the presence of any metastable or kinetically controlled aggregates [118], care 
was taken so that all samples were treated in the same manner. Specific conductance, κ (in 
μS/cm) of all the surfactant solutions was measured as a function of concentration with a 
SevenEasy
TM
 S30 Conductivity Meter (METTLER TOLEDO, Switzerland). All 
measurements were performed in a double-walled glass titration cell (Fisher Scientific, USA) 
with the temperature being controlled at 296.15 K (23 ± 0.05
0
C) using Lauda Ecoline RE 304 
(Lauda, Germany) circulating water bath. Concentrated surfactant solution was successively 
added to 40 mL of Milli Q water contained in the titration cell. Sufficient time was allowed 
between consecutive additions for the system to equilibrate. The specific conductance (κ) as 
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a function of surfactant concentration was measured using an InLab
®
 730 conductometer 
probe (electrode) with a cell constant of 0.56 cm
–1
 and with inbuilt automatic temperature 
compensation (ATC). The conductometer was initially calibrated with standard solutions of 
specific conductivity 1413 μS/cm. All the conductometric titrations were carried out in 
duplicate for each of the gemini surfactants studied. 
 
3.2.4 Krafft Temperature measurement 
Saturated aqueous solutions (~1.5 mM, >> CMC for all surfactants) were prepared, 
separately, for each gemini surfactant, by sonication at 55
0
C. After cooling at room 
temperature (25 – 300C) they were held at 40C in a refrigerator for at least 45 – 48 hours [81, 
94], until precipitates of the hydrated surfactant crystals appeared. The precipitated solutions 
were then introduced into conductivity titration cell described in the previous section. 
Temperature was controlled to ± 0.05
0
C with a Lauda Ecoline RE 304 (Lauda, Germany) 
circulating water bath. The initial temperature was set to 5
0
C and then was gradually 
increased by 1
0
C in every 10 minutes up to 55
0
C. The temperature point where the 
precipitated (hydrated crystals of gemini) gemini solution became completely clear was 
detected by visual inspection through the transparent titration cell and recorded as the Krafft 
temperature (TK). Krafft temperature determinations were carried out in duplicate for each 
gemini surfactant. 
 
3.2.5 Density and pH measurement 
To measure the density and pH of the GS solutions, stock solutions for each gemini 
surfactant, by sonication at 55
0
C were prepared at a specific concentration (~1.5 mM, >> 
CMC for all surfactants). The density was measured in triplicate using a 2 mL pycnometer 
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(Fisher Scientific, USA) at 55
0
C (as this temperature is above the TK for all the eight GSs) 
using the equation for specific gravity (Equation-3.1) as the following: 
 
Density of a liquid (in g/mL units), DL = (ML x DW) / MW                 3.1 
Where, 
ML = Mass of the liquid at experimental temperature 
DW = Density of Milli Q water at experimental temperature (0.98 g/mL @ 55
0
C) 
MW = Mass of of Milli Q water at experimental temperature 
 
 
pH measurements were made in triplicate at 55
0
C using  an Accumet XL 60 dual 
channel pH meter (Fisher Scientific, USA) through the AccuCap™ Combination pH 
electrode (13-620-130) carrying the inbuilt ATC probe (13-602-19).  
 
3.2.6 Bacterial growth and extraction of plasmid 
 Before the extraction process of plasmids, a single colony of bacterial strain JM109 
[pNN9] (JM109 of Escherichia coli is a generous gift from Dr. Slavcev’s research group) 
was grown overnight (18 – 20 hours) in 5 mL of growth media [Luria-Bertani (LB) broth + 
Ampicillin (Ap) antibiotic (100 μg/mL)] in a temperature controlled bench-top shaker (New 
Brunswick Scientific Excella™ E24, Fisher Scientific, US) at 250 rpm and 370C with 
circulating air supply. A new batch of cells were grown overnight from that last day culture 
at 1:100 dilution in 50 mL of growth media (within a 250 mL Erlenmeyer flask), at the same 
temperature and rpm. After the overnight treatment, final culture was taken out from the 
shaker when the A600 ≈ 0.8 – 0.9, at which point indicates the exponential bacterial growth of 
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mid logarithmic phase [132]. As already mentioned, E.Z.N.A.
®
 Endo-Free Plasmid DNA 
Maxi Kit and E.Z.N.A.
®
 Plasmid DNA Maxi Kit (OMEGA bio-tek, Georgia, USA) were 
used for extraction of DNA for transfection and Zetasizer studies respectively. In both of the 
cases, standard centrifugation protocol was followed to extract the plasmids.  
An aliquot of 200 ng/μL plasmid solution (in Milli Q water) was prepared from the 
extracted plasmid stock and the pH of that solution was measured in duplicate while the 
average is reported (pH = 6.1 ± 0.2). The pH value of the plasmid solutions will help to 
extrapolate an assumption on the compatibility of the transfection complexes/nanoparticle 
formulation mixtures. The extracted plasmid stock was then immediately stored at – 200C 
freezer as recommended in the protocol. The estimated bacterial cell concentration in the 
extracted culture was calculated according to optical density readings where, OD600 (= 2 x 
A600). The DNA production efficiency and confirmation of the DNA size was assessed by 
agarose gel electrophoresis (AGE) (Alpha-Imager HP, Alpha Innotech, Cell Biosciences, 
USA). Finally, the concentration of the extracted plasmid were analysed by UV 
spectrophotometry (NanoDrop 2000, Fisher Scientific, USA). 
 
3.2.7 Confirmation of extracted plasmids: Agarose Gel Electrophoresis (AGE) 
The protocol followed for AGE was as described by Lee et al. (2012) with minor 
modification [141]. After casting the AGE tray and initial setup of the apparatus, the required 
volume (for ≥ 500 ng of plasmid) of the extracted plasmid sample, 1 L of the DNA-ladder 
standard (aka, control, 500 g /L, 1 kb size), and 6X Sample Loading Buffer/Dye solution 
(in glycerol) at a ratio of (Loading Buffer : Plasmid =) 1 : 5 was carefully pipetted, and 
separately mixed in appropriate combination (Ladder + Dye, and Samples + Dye) on 
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parafilm sheets (Curwood Parafilm M™ Laboratory Wrapping Film, Fisher Scientific, USA). 
After adjusting the final volume of the individual mixture(s) by adding Milli Q water, 10 L 
of each mixture was separately pipetted into the designated wells before running the power.  
The electrophoresis power (potential difference of 100 volts, and 3 amperes of 
current) was allowed to run until the blue dye approaches the end of the gel (generally >1.5 
hr, until clear band separation). As DNA diffuses within the gel over time, very light bands 
are difficult to see, and thus, the UV imaging (provided in the “Appendix” section) was done, 
shortly after cessation of electrophoresis, through an UV transilluminator at 302 nm. The 
pNN9 plasmid has a size of 5.6 kb in its normal covalently closed circular (CCC) form [132], 
and from the UV image of the AGE, the size of the pNN9 plasmid was confirmed. 
Experimentally extracted plasmid DNA mainly has two different forms of DNA: a closed 
circle supercoiled form (SC), and a nicked circular form (NC) as in small fractions [142]. In 
the UV images, the observed bands of closely similar intensity of the pNN9 plasmid near 5 
kb and 9 kb (approximately) region corresponding to the DNA ladder control suggested the 
existence of both topological form of plasmids within the extracted sample. Lastly, to 
confirm the purity of the extracted plasmid, A260/280 values from the NanoDrop 2000 
spectrophotometer were also recorded (provided in the “Appendix’ section) and confirmed 
with the values given in the extraction kit (within 1.8 – 2). 
 
3.2.8 Measurement of Particle size (diameter) and Zeta potential (ζ) 
Particle size and zeta potential were measured for all gemini surfactant solutions, as 
well as for nanoparticles prepared from gemini surfactant/DOPE, gemini surfactant/Plasmid 
DNA, and gemini surfactant/DOPE/Plasmid DNA combinations at various charge ratios. All 
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particle size & zeta potential measurements were made using a Malvern Zetasizer Nano ZS 
instrument (Malvern Instruments, Worcestershire, UK).   
 
3.2.8.1 Preparation of GS based nanoparticles 
3.2.8.1.1 Preparation of GSs stock solution 
For both the size and zeta potential measurements for all the eight GS, 1.5 mM 
solution were prepared after constant sonication at or above their respective Krafft 
temperature and then the solutions were filtered through 0.2 μm syringe filters (Thermo 
Scientific™ Nalgene™ Syringe Filters, US) immediately after solubilizing them to prepare 
the final stock solution for use. The following table (Table-3.1) enlists the molecular mass of 
all the GS with different counterions.  
 
Table-3.1: Molecular mass of 16 – 2 – 16 series of GS with eight different counterions  
16 – 2 – 16. 2Br – = 726.86 g/mole  16 – 2 – 16. 2GMP – = 1289.50 g/mole 
16 – 2 – 16. 2Cl – = 638.05 g/mole  16 – 2 – 16. 2UMP – = 1211.40 g/mole 
16 – 2 – 16. 2AMP – = 1257.50 g/mole  16 – 2 – 16. Malate – – = 699.124 g/mole 
16 – 2 – 16. 2CMP – = 1209.42 g/mole  16 – 2 – 16. Tartrate – – = 715.12 g/mole 
 
 
3.2.8.1.2 Preparation of 1 mM DOPE liposomal solution 
DOPE vesicles (1 mM) were prepared in Dulbecco’s Phosphate Buffer Saline (PBS) 
with modification of the procedures outlined according to Wettig et al. [143]. Here, lipid film 
hydration method (the most widely used method) was followed for the preparation of multi 
lamellar vesicles (MLVs) for a lipid, and the method consist of two [144] major steps –  
a) Formation of a Lipid Film  
b) Hydration of the Lipid Film/Cake  
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3.2.8.2 Formulation of nanoparticles and measurement of size and ζ-potential 
The prepared stock solutions of GSs and DOPE was sonicated for 30 minutes at the 
Krafft temperature of GSs and then filtered through Nalgen 0.20 μm and 0.45 μm syringe 
filters (Thermo Scientific, USA) respectively before using to formulate the nanoparticles. 
The same applies to the preparation of nanoparticles for in vitro transfections except that, the 
GS stock solutions and the DOPE-vesicle solution were prepared aseptically to avoid 
unforeseen contamination.  
Different aliquots of the 16 – 2 – 16 stock solution (0.8 μl, 2 μl and 4 μl per 0.4 μg 
DNA) were used to generate GS/DNA lipoplexes at 2:1, 5:1, and 10:1 N
+
/P
–
 charge ratios 
respectively. After 15 minutes of incubation at room temperature, different aliquots (3 μl, 7.6 
μl and 15.2 μl) of 1 mM DOPE vesicle solution (in DPBS) were added and then subsequent 
mixtures were further incubated for 20 minutes at room temperature to generate lipoplexes, 
of varying charge ratios, with a constant GS to DOPE ratio of 2 : 5. The following table 
(Table-3.2) was used as a blueprint for the formulation of nanoparticles. 
As mentioned earlier, particle sizes for plasmid, GS solutions, and the resulting 
plasmid-gemini (G+P) complexes & plasmid-gemini-DOPE (G+P+D) lipoplexes were 
measured by dynamic light scattering (DLS, where θ = 173°) using Malvern Zetasizer Nano 
ZS instrument (Malvern instruments, UK). A minimum of 700 μL sample volume was taken 
into DTS 1070 folded capillary cells / cuvette to measure both sizes and ζ-potentials of the 
respective samples, and Zetasizer software of version 7.11 was used for machine operation. 
Here, both the sizes & zeta potentials (ζ) values for all the samples mentioned in Table-3.2 
were measured at 25
0
C in quintuplicate and the averages (n = 5) were reported. 
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Table-3.2: Mapping of nanoparticles formulation based on GSs 
Formulation 
Compounds* 
GS + D + P 
(+/-  =10:1) 
GS + D + P 
(+/-  =5:1) 
GS + D + P 
(+/-  =2:1) 
GS + D GS P D 
Plasmid (P) 0.4 μg 0.4 μg 0.4 μg – – 0.4 μg – 
Gemini (GS) 
(1.5 mM) 
4 μL 2 μL 0.8 μL 4 μL 4 μL – – 
DOPE (D) 
(1 mM) 
15.2 μL 7.6 μL 3 μL 15.2 μL – – 15.2 μL 
Milli Q Water 50 μL 50 μL 50 μL 50 μL 50 μL 50 μL 50 μL 
 
* GS: Gemini Surfactant with 8 different counterions; D: DOPE SUV solution; P: pNN9 Plasmid solution 
 
 
3.2.9 In vitro Transfection Assay 
3.2.9.1 In vitro transfection assay in OVCAR-3 cells 
In vitro transfection experiments were carried out over 4 consecutive days, following 
a standard optimized protocol for OVCAR-3 transfection previously developed in our lab 
[145]. Cryopreserved OVCAR-3 cells from the liquid nitrogen (–1960C) cryopreservation 
storage system (Locator™ 6 Plus Thermolyne Rack and Box Systems, Thermo Scientific, 
US) were directly seeded in 75cm
2
 Nunc EasYFlask with filter cap (Thermo Scientific, US) 
in standard growth media [RPMI-1640 (HyClone, Thermo Scientific, US) supplemented with 
20% Fetal Bovine Serum (FBS) (HyClone, Thermo Scientific, US), 1% Bovine pancreas 
insulin solution in HEPES buffer (Sigma Aldrich, US), and 1% penicillin-streptomycin 
(Fisher Scientific, USA)].  The cells were grown at 37
0
C with 5% CO2 in a Thermo Forma II 
series water jacketed incubator (Fisher Scientific, USA), and maintained at 70-80% (< 80% 
is recommended) confluency prior to transfection.  
On the first day of the experiment cells were detached and seeded at a concentration 
of 50,000 cells/well into a BioLite 24-well cell culture plate (Thermo Scientific, US), and 
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were allowed to grow and to get adhered upon the surfaces of each well for ~24 hours. On 
day 2, the seeded cells were washed with DPBS and fresh RPMI-1640 (without FBS or 
antibiotics) to which 1 % insulin was added. Transfection lipoplexes were prepared in Opti-
MEM (Gibco, Invitrogen) and the resulting lipoplexes were added drop-wise at amounts 
corresponding to 0.4 μg of DNA per well. Transfection with 1.2 μl of LipofectamineTM 2000 
(1 mg/mL, Invitrogen) per 0.4 μg of DNA, was also carried out according to the 
manufacturer's protocol and served as a positive control. Cells were also transfected with 
naked plasmid, plasmid complexed with gemini surfactant alone, DOPE only, and DOPE 
complexed with gemini surfactants (Table-3.3 was used as a template), as controls. The 
mapping for transfection mixtures is given in Table-3.4. After adding transfection 
formulations, cells were incubated at 37
0
C with 5% CO2 for 5 hours before the transfection 
medium was replaced by fresh RPMI-1640 supplemented with 20% FBS & 1% insulin. Cells 
were further grown until 24 hours post-transfection at which point  the cells were collected, 
washed, and re-suspended in DPBS in Nunc 15mL Conical Sterile Polypropylene Centrifuge 
Tubes (Thermo Scientific, US) for flow cytometry analysis (Day 4). All the experiments for 
each transfection formulation were done in triplicate; each experiment was done twice in 
parallel, for which average (n = 6) transfection efficiencies and cell viabilities are reported.  
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3.2.9.2 Flow cytometry 
Transfection efficiency (TE) was determined 24 hours after transfection by 
determination of EGFP fluorescence using a Guava easyCyte™ 8HT benchtop flow 
cytometer (EMD Millipore, Merck KGaA, Billerica, MA) which is a part of Dr. Spagnuolo’s 
lab in the School of Pharmacy. Flow cytometry analysis gives information about the 
comparative expression of green fluorescence which serves as an indicator of transfection 
efficiency in terms of % GFP (green fluorescence protein) expression. The % GFP 
expression indicates the percentage of cell population expressing GFP over residual 
fluorescence of non-transfected cells (no treatment category) or transfected with only pDNA 
and lipid mixture alone [146].  
Briefly, cells were detached by trypsinization, and then centrifuged at 0 – 40 C and 
1800 rpm for 10 min. The resulting cell pellets were washed and suspended with 1000 μL of 
DPBS, followed by another centrifugation step, and finally resuspended in 200 μL of DPBS. 
The resuspended cells were then seeded again in a flat bottom 96 well plate (SARSTEDT, 
Fisher Scientific, USA) as per machine specifications. To determine the cytotoxicities after 
transfection by detecting dead cells, 2.5 μL of propidium iodide (PI, 50 mg/mL) was added to 
each sample and incubated in an ice bath for at least 30 min before the flow cytometer 
analysis. The analyzed data are expressed as Mean (n = 6) ± SD (standard deviation) 
 
  
CHAPTER-3: MATERIALS & METHODS 
63 
 
Table-3.3: Transfection formulation template for each well  
 
Formulation 
Compounds 
Plasmid 
(P) 
Gemini 
GS (1.5 mM) 
DOPE (D) 
(1 mM) 
Opti-MEM 
(1X) 
Lipofec- 
-tamine 
2000 
# of 
wells 
GS + D + P 
(+/-  =10:1) 
0.4 μg 4.04 μL 15.2 μL 50 μL – 7, 7, 7 
(Inc. 1 
extra for 
each 
GS) 
GS + D + P 
(+/-  =5:1) 
0.4 μg 2.02 μL 7.6 μL 50 μL – 
GS + D + P 
(+/-  =2:1) 
0.4 μg 0.81 μL 3.03 μL 50 μL – 
GS + D 
(+/-  =10:1) 
– 4.04 μL 15.2 μL 50 μL – 7, 7, 7 
(Inc. 1 
extra for 
each 
GS) 
GS + D 
(+/-  =5:1) 
– 2.02 μL 7.6 μL 50 μL – 
GS + D 
(+/-  =2:1) 
– 0.81 μL 3.03 μL 50 μL – 
GS + P 
For (+/- =10:1) 
0.4 μg 4.04 μL – 50 μL – 7, 7, 7 
(Inc. 1 
extra for 
each 
GS) 
GS + P 
For (+/- =5:1) 
0.4 μg 2.02 μL – 50 μL – 
GS + P 
For (+/-  =2:1) 
0.4 μg 0.81 μL – 50 μL – 
D (Lipid only) 
For (+/-  =10:1) 
– – 15.2 μL 50 μL – 
7, 7, 7  
(Inc. 1 
extra) 
D (Lipid only) 
For (+/-  =5:1) 
– – 7.6 μL 50 μL – 
D (Lipid only) 
For (+/-  =2:1) 
– – 3.03 μL 50 μL – 
P 
(Plasmid only) 
0.4 μg – – 50 μL – 
7 (Inc. 1 
extra) 
L (Lipofectamine 
2000) + Plasmid 
0.4 μg – – 50 μL 1.2 μL 
13 (Inc. 
1 extra) 
NT (No 
Treatment) 
– – – 50 μL – 
13 (Inc. 
1 extra) 
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Table-3.4: Mapping for BioLite 24-well multidishes for transfection 
 
Plate I: GDP Plate: 
 
 1 2 3 4 5 6 
A (10:1) D + G + P D + G + P D + G + P D + G + P D + G + P D + G + P 
B (5:1) D + G + P D + G + P D + G + P D + G + P D + G + P D + G + P 
C (2:1) D + G + P D + G + P D + G + P D + G + P D + G + P D + G + P 
D – – – – – – 
 
Plate II: GD Plate:  
 
 1 2 3 4 5 6 
A (10:1) D + G D + G D + G D + G D + G D + G 
B (5:1) D + G D + G D + G D + G D + G D + G 
C (2:1) D + G D + G D + G D + G D + G D + G 
D – – – – – – 
 
Plate III: GP Plate:  
 
 1 2 3 4 5 6 
A (10:1) G + P G + P G + P G + P G + P G + P 
B (5:1) G + P G + P G + P G + P G + P G + P 
C (2:1) G + P G + P G + P G + P G + P G + P 
D P P P P P P 
 
Plate IV: D Plate:  
 
 1 2 3 4 5 6 
A (10:1) D D D D D D 
B (5:1) D D D D D D 
C (2:1) D D D D D D 
D – – – – – – 
 
Plate V: Control Plate: 
 
 1 2 3 4 5 6 
A (10:1) NT NT NT NT NT NT 
B (5:1) NT NT NT NT NT NT 
C (2:1) L + P L + P L + P L + P L + P L + P 
D L + P L + P L + P L + P L + P L + P 
 
Here, P = Plasmid, L = Lipofectamine
TM
 2000, G = GSs @ 1.5 mM, D = DOPE @ 1 mM, NT = no treatment
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4. Results & Discussion 
4.1 Syntheses and 
1
H NMR Characterization of GSs 
 The average yields for the synthesis of the gemini surfactants examined in this 
work are provided in Table 4.1, although we were not really concerned about the actual yield 
from the syntheses. The yield obtained for the synthesis of the chloride salt is markedly low 
compared to the other surfactants prepared; especially given that this synthesis involved only 
a single synthetic step as compared to the organic counterion salts.  This low yield for the 16-
2-16 surfactant is attributed to the lower reactivity of 1–chlorohexadecane relative to 1–
bromohexadecane in an SN2 type reaction [147]. Confirmation of the gemini surfactant 
structures was obtained by 
1
H NMR (all the spectra have been provided in the “Appendix” 
section).  Assignment of protons in the 
1
H NMR spectra for the 16-2-16 surfactant is 
illustrated in Figure 4.1. Chemical shift data for each surfactant is summarized below. 
 
Table-4.1: Average yield of the gemini surfactants after syntheses 
Name of the final 
products 
Name of the reactants Purification 
Average yield*of 
final products 
(%) 
16 – 2 – 16 . 2Br – Cetyl Bromide, TMEDA Recrystallization 65 
16 – 2 – 16 . 2Cl – Cetyl Chloride, TMEDA Recrystallization 30 
16 – 2 – 16 . 2Ac – Gemini-Br –, Ag-Acetate Recrystallization 70 
16 – 2 – 16 . 2AMP – Gemini-Ac –, AMP.H2O Lyophilization 75 
16 – 2 – 16 . 2CMP – Gemini-Ac –, CMP Lyophilization 85 
16 – 2 – 16 . 2UMP – Gemini-Ac –, UMP Lyophilization 85 
16 – 2 – 16 . 2GMP – Gemini-Ac –, GMP Lyophilization 80 
16 – 2 – 16 . Tartrate – – Gemini-Br –, Ag-Tartrate Recrystallization 50 
16 – 2 – 16 . Malate – – Gemini-Br –, Ag-Malate Recrystallization 55 
 
*Yield = (Actual yield / Theoretical yield) x100  
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Figure-4.1: Assignment of protons in 16-2-16 gemini surfactant structure used in the 
interpretation of 
1
H NMR spectra. 
 
 
Chemical shift data for each surfactant: 
a) 16-2-16.2X 
–
 (X 
–
 = Br 
–
 or Cl 
–
). 
1
H NMR (300 MHz, CD3OD, 25 °C, δ ppm):  
4.75 (4H, t); 3.69 (4H, t); 3.49 (12H, m); 1.78 (4H, m); 1.35 (4H, m); 1.23 (48H, m); 0.83-
0.87 (6H, t). 
b) 16-2-16.2AMP 
–
. 
1
H NMR (300 MHz, D2O, 25 °C, δ ppm): 
8.36 (1H, s); 8.07 (1H, s); 5.98 (2H, d); 4.66 (4H, t); 4.38 (2H, m); 4.22 (2H, m); 4.03 (4H, 
m); 3.81 (4H, t); 3.35 (4H, t); 3.17 (12H, m); 1.61 (4H, m); 1.19 (4H, m); 1.05 (48H, m); 
0.67 (6H, t).   
c) 16-2-16.2UMP 
–
. 
1
H NMR (300 MHz, D2O, 25 °C, δ ppm): 
7.95 (1H, d); 5.91 (1H, d); 5.86 (1H, s); 4.29 (2H, m); 4.17 (2H, m); 4.05 (4H, m); 3.87 (4H, 
t); 3.46 (4H, t); 3.23 (12H, m); 1.75 (4H, m); 1.34 (4H, m); 1.19 (48H, m); 0.79 (6H, t). 
d) 16-2-16.2CMP 
–
. 
1
H NMR (300 MHz, D2O, 25 °C, δ ppm): 
7.99 (1H, t); 6.08 (1H, d); 5.90 (2H, d); 4.25 (2H, m); 4.18 (2H, m); 4.09 (4H, m); 4.02 (4H, 
t); 3.39 (4H, t); 3.21 (12H, m); 1.70 (4H, m); 1.32 (4H, m); 1.22 (48 H, m); 0.82 (6H, t). 
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e) 16-2-16.2GMP 
–
. 
1
H NMR (300 MHz, D2O, 25 °C, δ ppm): 
7.99 (1H, d); 5.79 (1H, d); 4.64 (2H, t); 4.38 (2H, m); 4.16 (2H, m); 3.98 (4H, m); 3.81 (4H, 
t); 3.36 (4H, t); 3.15 (12H, m); 1.63 (4H, m); 1.14 (4H, m); 1.11 (48H, m); 0.72 (6H, t). 
f) 16-2-16.Tartrate 
– –
. 
1
H NMR (300 MHz, D2O, 25 °C, δ ppm): 
4.20 (2H, d); 3.84 (4H, t); 3.39 (4H, t); 3.18 (12H, m); 1.68 (4H, m); 1.28 (4H, m); 1.23 
(48H, m); 0.81 (6H, t). 
g) 16-2-16.Malate 
– –
. 
1
H NMR (300 MHz, D2O, 25 °C, δ ppm): 
4.11 (1H, t); 3.81 (4H, t); 3.35 (4H, t); 3.14 (12H, m); 2.22-2.26 (2H, m); 1.65 (4H, m); 1.27 
(4H, m); 1.19 (48H, m); 0.77 (6H, t). 
 
4.2 Physicochemical characterization of Gemini Surfactants 
As mentioned in the “Objective” section 2.3, various techniques were employed for 
physicochemical characterization the gemini surfactants. Tensiometry and conductometry 
were used to characterize the aggregation behavior of gemini surfactants. Krafft temperature, 
solubility of organic counterions, density, pH, viscosity, and foamability measurements were 
done as a part of physicochemical characterization for all the gemini surfactants. The data for 
solubility, viscosity and foamability measurements have been provided in the “Appendix” 
section of this dissertation. 
  
4.2.1 Characterization of Gemini Surfactant Aggregation using Tensiometry and 
Conductometry 
We employed the tensiometric and conductometric method to study the micellization 
of the 16-2-16 series of gemini associated with eight different counterions in the structure. 
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The majority of literature studies in which the impact of counterion on surfactant aggregation 
is examined use added salt as opposed to exchange of the counterion [114, 115, 134, 138, 
148-162]. It should be noted that the effects of added salt, as opposed to the exchange of 
counterion can result in dramatic differences in aggregation properties, in part due to the 
increase in ionic strength which has a major effect to dissociate the counterions of the GSs, 
and partly because the incomplete removal of the original counterion may still affect the 
surface and aggregation properties [134]. 
 
4.2.1.1 CMC and head group area determinations by Tensiometry 
The micellization behavior and surface activity of an ionic surfactant is mainly 
dependent on the associated counterion [108]. The variations of the surface tension, γ with 
the semi-log concentration, Log C (molar) at 298.16 K (for gemini-tartrate, T=308.16 K) for 
16-2-16 series of gemini surfactant are shown in Figure-4.2. From the figure, it can be clearly 
observed that the surface tension decreases sharply with an increase in surfactant 
concentration until the critical micelle concentration is reached.  
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Figure-4.2: Surface tension vs Log (Conc.) plots of 16-2-16 series of surfactants   
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The measured CMC and other parameters of these gemini surfactants in solution are 
listed in Table-4.2 From the results, it can be seen that for the inorganic counterions (Br
-
 and 
Cl
-
) 16-2-16 has a low CMC, the magnitude of which is dependent on the hydrophobicity of 
the halide. Specifically, since the bromide is more hydrophobic than chloride, the CMC for 
the 16-2-16 bromide gemini surfactant (30.8 μM) is lower than that observed for the 16-2-16 
chloride surfactant (44 μM).   For the small organic counterions (malate and tartrate), this 
trend is reversed, with the more hydrophobic malate ion (having one fewer hydroxyl 
substituents) having a higher CMC as compared to the less hydrophobic tartrate ion. 
 
Table-4.2: Measured CMC and other parameters of gemini surfactants associated with 
different counterions 
 
Gemini  
Surfactants 
γcmc 
(mN/m) 
Πcmc 
(mN/m) 
CMC 
 (μM) 
10
6Γmax 
(molecules 
/ m
2
) 
Amin            
(nm
2
 / 
molecule) 
ΔG0mic                              
(KJ / 
mole) 
ΔG0ads                              
(KJ / 
mole) 
*16-2-16.2Br 
–
 39.6 30.8 30.8 ± 7 1.4 1.23 -35.7 -59.0 
16-2-16.2Cl 
–
 42.6 28.1 44.0 ± 9 1.3 1.28 -34.9 -56.3 
16-2-16.2AMP 
–
 55.5 13.4 1.1 ± 0.2 1.3 1.36 -45.6 -55.7 
16-2-16.2CMP 
–
 59.9 10.7 1.3 ± 0.0 1.6 1.03 -43.5 -50.2 
16-2-16.2UMP 
–
 55.9 14.5 1.1 ± 0.0 1.4 1.25 -44.1 -55.0 
16-2-16.2GMP 
–
 55.8 14.7 0.9 ± 0.0 2.1 0.78 -44.5 -51.4 
16-2-16.Tartrate 
– 
 
–
 50.4 19.9 1.5 ± 0.1 1.7 0.95 -43.2 -54.7 
16-2-16.Malate 
– 
 
–
 52.3 18.2 1.6 ± 0.2 2.0 0.82 -43.0 -52.1 
 
*Amin for the 16-3-16.2Br 
- was found to be 1.21 nm2/molecule [163] 
 
 
According to Collins and Washabaugh [164], the ions which exhibit strong 
interactions with water are known as kosmotropic ions (structure makers). On the other hand, 
the ions which are less hydrated and thus less effective in organizing surrounding water 
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molecules are termed as chaotropic ions (structure-breakers) [164]. For inorganic 
counterions, ions with low charge density and larger radii (e.g. bromide) typically have a 
stronger chaotropic effect. Hydrophobic inorganic counterions are more polarizable and are 
least hydrated in aqueous solution; and being chaotropic in nature, they destroy the structure 
of water in the vicinity of the counterion leading to reduced CMC values, favoring 
micellization [123].  
At the end of 19
th
 century, Hofmeister proposed that the influence of ions on the 
precipitation of proteins in salt solutions followed a particular pattern, leading to the 
commonly referred to "Hofmeister series" of ions [164, 165]. Although Hofmeister effects 
for macromolecules in aqueous solution are ubiquitous (for example enzyme activity, protein 
stability, protein–protein interactions, optical rotation of sugar and amino acids, as well as 
bacterial growth) [166], this pattern of behavior is also observed in many physico-chemical 
mechanisms including the phenomena of micellization of charged surfactants [167]. Cremer 
et al. (2006) reported that the direct interactions existing between the ions and 
macromolecules are predominantly responsible for most aspects of this pattern [166]. 
Furthermore, Warr et al. (2004) reported a study to evaluate the affinity of some anions (Br
-
, 
Cl
-
, I
-
, NO3
-
) to the head groups of gemini surfactants at the air/water interfaces and their 
subsequent effects on gemini aggregation. The order of affinity of the counterions for gemini 
surfactant descends I
-
 > NO3
-
 > Br
-
 > Cl
-
, which follows to the Hofmeister series [168].  
Similarly, Manet et al. (2010) reported that the CMC of gemini surfactants with 
monatomic counterions generally increases according to the Hofmeister series: I
-
 < NO3
-
 ∼ 
Br
-
< Cl
-
 < F
-
 ∼ C2
-
 < PH. On the other hand, due to entropic reasons, micellization is 
disfavored for large polyatomic anions, although they have a lower hydration number, and 
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similar hydrophobicity to the monatomic counterions [123]. Our results for the gemini 
halides were in agreement with the previously reported trends. 
The packing densities of surfactants at the air-water interface are important to the 
interpretation of the surface activities of surfactants [80, 84, 169, 170]. The surfactant 
molecule occupies an area at the air/water interface (i.e. Amin) which should reflect their 
packing densities [80, 170, 171]. The surface excess concentration Γmax (also known as the 
Gibbs surface free excess) and the minimum surface area occupied/molecule, Amin at the air-
water interface can be calculated according to the Gibbs adsorption isotherm [108, 172]. 
 
𝛤𝑚𝑎𝑥 =
−1
2.303𝑛𝑅𝑇 
𝑑𝛾
𝑑𝑙𝑜𝑔𝐶
                   4.1 
and, the equation 
Amin = (NAΓmax) 
– 1
 × 1018                    4.2 
 
where, R = 8.314 J·mol
−1
·K
−1
, T = 298.15 K with surface tension (γ) expressed in N/m, NA is 
Avogadro’s number (6.023 × 1023 mol−1), and n is the number of species the surfactant 
dissociates into. For monovalent counterions in combination with the gemini surfactant, a 
value n = 3 generally used, for the case of divalent counterions combined with the gemini, a 
value of n = 2 is used [94, 170, 172-174].  
The CMC, average surface tension at the CMC (γcmc), average surface pressure (Πcmc) 
Γmax, Amin, the average Gibbs free energy of micellization (∆G
0
mic), and the standard free 
energy of adsorption (∆G0ads) have been determined from the tensiometry measurements and 
are listed in Table-4.2. ∆G0mic and G
0
ads can be calculated according to [80, 175] –  
 
 ∆G0mic = RT ln XCMC          4.3 
 ∆G0ads = ∆G
0
mic – ПCMC / max        4.4 
CHAPTER-4: RESULTS & DISCUSSION 
73 
 
where, XCMC is the CMC in mole fraction units [i.e. CMC / (CMC + 55.6), where 55.6 is the 
number of moles of water per litre], ПCMC is the surface pressure at CMC (ПCMC = γ0 – γcmc: 
γ0 is the surface tension of pure water). 
Both ∆G0mic and G
0
ads are strongly negative, indicating that micelle formation and 
adsorption at the air-water interface are spontaneous processes.  From our results, it is clear 
that a change in the counterion impacts the aggregation of the gemini surfactant, rather 
dramatically. The trends in ∆G0mic and G
0
ads as well as Amin are similar to that observed for 
the CMC, again likely related to the relative hydrophobicity of the counterions. 
Although the presence of hydroxyl groups in their structures makes the NMP 
counterions hydrophilic in nature, from the solubility data (in Appendix section) it was found 
that the solubility of the NMP counterions follows the sequence: UMP > AMP > CMP > 
GMP. Overall, these four counterions affect the CMC of 16-2-16, reducing it by almost 40-
fold compared to that for the gemini halides. Although no conclusion can be drawn from our 
data based on the hydrophilicity of these counterions (i.e. the CMC values along with the 
other parameters does NOT follow the trend of increasing hydrophobicity), all the gemini-
NMPs have approximately the same energies of micellization and adsorption. Again, the 
negative values of both ΔG0mic and ΔG
0
ads signify that the adsorption of these 16-2-16 series 
of surfactants at the air/water interface as well as micellization in the aqueous solution is 
spontaneous. 
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4.2.1.2 Electrical Conductivity Measurements: Conductometry 
The CMC and degree of micelle ionization for an ionic surfactant can be determined 
from a plot of the electrical conductivity (κ) of the solution as a function of surfactant 
concentration. The conductance increases linear with increasing concentration, as the number 
of ions present in solution also increases. At the CMC, aggregation takes place, at which 
point the ions no longer move independently from one another, resulting in a dramatic 
decrease in slope for the conductivity vs. concentration curve. A linear fit [82, 176-178] of 
the conductivity above and below the CMC is used to determine the value of the CMC; the 
point of intersection of the two linear fits is equal to the CMC [134, 179]. The degree of 
micelle ionization of the micelles, α can be calculated from the ratio of the slopes of the 
linear regions above and below the CMC [134]. The degree of ionization α can also be 
replaced by the degree of counterion association to micelle, β obtained by the relationship α 
= 1 – β. Both the terms α and β are used to reflect the extent of counterion binding to the 
micelles. A larger value of α, corresponds to greater dissociation of the counterions from the 
surface of the micelle, and indicates weaker binding of the counterions to the micelles [134].  
The conductance plots for all surfactants are shown in Figure 4.3, and calculated 
values of the CMC and α are provided in Table-4.3. Excellent agreement is observed 
between the CMC determined from conductivity measurements and those determined from 
surface tension. Again, we see a pronounced effect of counterion exchange on the CMC and 
Gibbs free energy of micellization, although surprising, the effect of counterion exchange on 
α was minimal.  
  
CHAPTER-4: RESULTS & DISCUSSION 
75 
 
0
2
4
6
8
10
12
14
16
0.E+00 2.E-05 4.E-05 6.E-05
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
b) 16-2-16.2Cl- 
0
2
4
6
8
0.E+00 2.E-05 4.E-05 6.E-05
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
a) 16-2-16.2Br- 
0
2
4
6
8
0.E+00 4.E-07 8.E-07 1.E-06 2.E-06
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
d) 16-2-16.2UMP- 
0
2
4
6
8
10
12
0.E+00 4.E-07 8.E-07 1.E-06 2.E-06
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
c) 16-2-16.2AMP- 
0
2
4
6
8
0.E+00 4.E-07 8.E-07 1.E-06 2.E-06
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
f) 16-2-16.2GMP- 
0
2
4
6
0.E+00 6.E-07 1.E-06 2.E-06 2.E-06
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
e) 16-2-16.2CMP- 
0
1.5
3
4.5
0.E+00 7.E-07 1.E-06 2.E-06 3.E-06 4.E-06
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
h) 16-2-16.Malate- - 
0
2
4
6
8
0.E+00 7.E-07 1.E-06 2.E-06 3.E-06 4.E-06
C
o
n
d
u
ct
an
ce
 (
μ
S/
cm
) 
Conc. (M) 
g) 16-2-16.Tartrate- -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4.3: Specific conductance vs Concentration for the 16-2-16 gemini surfactants with 
various counterions.  The intersection of the lines of best fit give the CMC, and the ratio of 
the slopes above and below the CMC (S2/S1) provides the degree of micelle ionization, . 
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Generally, a higher degree of micelle ionization indicates that head group repulsion 
would play an important role in determining the structure of the micelle aggregates [94, 180]. 
The head groups of the monomer molecules in a micelle formed from ionic surfactants are 
charged by a fraction, 1 – α, of the counterions that are condensed onto the surface of the 
micelle [181]. A cationic gemini surfactant with a higher α would be a better candidate to 
condense proteins or other polyelectrolytes, such as DNA, as anionic molecules may more 
easily be able to replace the counter ions at the surface of the micelle to form compact 
complexes of much smaller size [94]. Being highly polarizable, the organic counterions 
enhance their binding at the micellar surface, and also decrease the electrostatic repulsion 
between the head groups of the surfactant molecules in the micelle, thus lowering both CMC 
and α [134]. 
 
Table-4.3: CMC and degree of micellization values of GSs associated with eight different 
counterions measured by conductometric method 
 
Gemini 
Surfactants 
Average CMC 
(μM) 
Average Degree of 
Micelle Ionization 
(α) 
Average Gibb's Free 
Energy of Micellization 
(KJ/mole) 
*16-2-16.2Br 
–
 26.8 ± 0.8 0.17 ± 0.002 -70.7 ± 0.3 
16-2-16.2Cl 
–
 31.4 ± 1.2 0.22 ± 0.013 -67.2 ± 0.5 
16-2-16.2AMP 
–
 0.8 ± 0.01 0.21 ± 0.001 -90.8 ± 0.2 
16-2-16.2CMP 
–
 1.1 ± 0.01 0.20 ± 0.001 -89.2 ± 0.1 
16-2-16.2UMP 
–
 0.8 ± 0.003 0.20 ± 0.001 -91.5 ± 0.2 
16-2-16.2GMP 
–
 0.8 ± 0.02 0.19 ± 0.010 -92.2 ± 0.9 
16-2-16.Tartrate 
–
 
–
 1.3 ± 0.01 0.21 ± 0.003 -63.2 ± 0.1 
16-2-16.Malate 
–
 
–
 1.3 ± 0.02 0.24 ± 0.015 -61.8 ± 0.5 
 
* Degree of micelle ionization (α) for 16-3-16.2Br – was found to be 0.35 [163] 
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The Gibbs free energy of micellization (ΔGmic) was calculated from the following 
equations [134]. As the degrees of micelle ionization of the micelles (α) values are readily 
available directly from the conductometric plots, literature suggests using these equations 
[134] to calculate the ΔGmic more accurately, instead using the equation-4.3 used in case of 
tensiometry: 
 
ΔGmic = RT (1+2β) ln (CMC) – RT ln 2   [For monovalent counterions]          4.5 
ΔGmic = RT (1+β) ln (CMC / 2)   [For divalent counterions]           4.6 
 
where, T = 298.16 K; R = 8.314 J/mole/K; β = (1 – α); α = (Slope–2 / Slope–1); from 
Specific conductance (μS/cm) vs. Concentration (M) curve. The CMC values obtained from 
tensiometry and conductometry methods were approximately close and in good agreement, 
but the free energy of micellization was drastically different due to application of different 
equations [94, 108] and experimental technique.  
 
4.2.2 Krafft Temperature 
Generally for cationic and anionic surfactants, the solubility in water undergoes an 
abrupt increase at a particulate temperature. This temperature is known as the Krafft 
temperature (TK) and is the minimum temperature at which point the hydrated surfactant 
becomes soluble and is judged visually to be the point of complete clarification of a turbid 
saturated solution of surfactant [181-184]. Below TK, a gel or precipitate is formed [118] and 
the surfactants remain in crystalline (hydrated crystals) form [80]. Hydrophobic tail lengths, 
the nature of the surfactant head group and the nature of the associated counterions are all 
key parameters in determining TK. Generally, the TK of a conventional monomeric and ionic 
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surfactant is found to increase with increasing the length of the alkyl chain and decrease with 
increasing the size of the head group [182]. As such, the double tailed gemini surfactants 
with longer chain lengths have higher TK [137].  
The inorganic bromide and chloride counterions are more polarizable, less 
hydrophilic and as a result less hydrated [123]. As such the more hydrophobic bromide 
counterion results in a Krafft temperature higher than that for the chloride counter ion (Table 
4.8). Tartaric acid has one additional hydroxyl group in its structure as compared to malic 
acid, resulting in increased hydrogen bonding in an aqueous solution of tartaric acid leading 
to decreased solubility of tartrate ions at room temperature. As the temperature increases, the 
Brownian motion of the water molecules increases exponentially and thus, the existing 
intermolecular hydrogen bonds disrupts leading to the solubility of tartaric acid at a higher 
temperature. Consequently, the TK for gemini-tartrate was found higher than the gemini-
malate. The solubilities of the NMPs at different temperatures decreases according to this 
sequences: UMP > AMP > CMP > GMP, found from the solubility test (see “Appendix” 
section). With the exception of AMP and CMP, the Krafft temperatures follow the same 
trend (Table 4.4), with the Krafft temperature of GMP being the highest at 55
0
C.  
 
4.2.3 Determination of pH, and density 
Table-4.4 also summarizes the average values for pH, and density measurements for 
our series of gemini surfactants.  Counterions associated with the gemini structure clearly 
impact the pH of the gemini surfactant in solution. Among the eight gemini surfactants 
examined, the UMP counterion makes the resulting gemini solution most acidic whereas 
chloride ions render the gemini solution almost neutral. The optimum pH required for 
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mammalian cell growth is pH 6.9 – 8 [185] but, it has been reported that the transfection 
efficiency of the non-viral vector, chitosan in human-lung carcinoma A549 cells was higher 
at pH 6.9 than that at pH 7.6 [186]. In this project, both the media (RPMI 1640 and Opti-
MEM
®
 I) that we employed for transfection assays utilize a sodium bicarbonate buffer 
system which was provided from the 5–10% CO2 environment of the incubator to maintain 
the physiological pH for cell growth. Considering this bicarbonate buffer as a weak system 
and given the pH data of the 16-2-16 series of gemini surfactants in hand, it is suggested that 
the change in pH of the overall transfection nanoparticles due to change of pH for the 
presence of gemini will probably affect the transfection efficiency as well as cell viability. 
Although the quaternary ammonium head group of the surfactants undoubtedly contributes to 
cytotoxicity [187], alteration of pH could be another factor contributing to cytotoxicity. 
Generally, surfactant intercalation into the cell membrane leads to changes in the 
membrane’s molecular organization and increases membrane permeability that results in cell 
lysis [187], and decreased cell viability.  
 
Table-4.4: Krafft temperature, pH, and density measurements data for GSs. 
 
Liquid / Solution 
Krafft Temp 
(
0
C) 
pH 
Average Density                      
(Kg/m
3
) 
Milli Q Water N/A 6.9 986.0 
16 – 2 – 16 . 2Br – 55 3.8 987.1 
16 – 2 – 16 . 2Cl – 40 6.3 987.5 
16 – 2 – 16 . 2AMP – 45 3.4 988.4 
16 – 2 – 16 . 2CMP – 35 3.6 1026.4 
16 – 2 – 16 . 2UMP – 4 3.1 987.9 
16 – 2 – 16 . 2GMP – 55 4.6 988.9 
16 – 2 – 16 . Tartrate – – 50 3.8 990.3 
16 – 2 – 16 . Malate – – 25 5.0 991.6 
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Variations in counterions have a less prominent effect on the average density of the 
16-2-16 series of surfactants, again shown in Table-4.4. Comparatively very subtle increase 
in density was observed for the gemini-CMP solution probably due to their actual 
morphological shapes and packing densities. The rest of the gemini surfactants have 
comparable densities (all approximately that of pure water), likely due to their similarities in 
packing and self-assembly behaviour. No notable patterns of changes in densities based on 
variation of counterions were found to correlate with the solubility data of the counterions, 
although there is no direct or inverse relationship exists between the density and solubility. 
 
4.3 Characterization of 16-2-16 GS aggregates by size and zeta potential measurements 
4.3.1 Size and zeta potential of extracted plasmid 
 It has already been confirmed the presence of supercoiled pNN9 plasmid (CCC) in 
our extracted samples, mentioned in the section 3.2.8. Despite the fact that pNN9 was the 
larger sized plasmid [79], the DNA supercoiling reduced the overall size and the average size 
of the pNN9 plasmid solution was found at 414 (± 15) nm with a polydispersity index (PDI) 
of 0.52. Although the DNA supercoiling can mask a fraction of the negative charges attained 
from the intramolecular phosphate groups, resulting to a lower effective negative charge 
[188, 189] for pNN9 (CCC), our results of measured zeta potential values were found at –33 
(± 0.5) mV. These negative zeta potentials of the pNN9 plasmids (CCC) denoted significant 
surface charges for extensive electrostatic interaction with the cationic 16-2-16 gemini 
surfactant, leading to complete counterion release and reduced head group repulsions. 
Reduced intermolecular head group repulsion between the surfactant molecules will ensure 
better DNA encapsulation leading to more uniform aggregates.  
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4.3.2 Size and zeta potential of DOPE vesicles 
 The average size of the DOPE vesicles was found to be 124 ± 8 nm with a PDI of 
0.46.  This value was in excellent agreement with the value reported by Wettig et al. [143]. 
The average zeta potential for the DOPE vesicles was found to be –30 ± 2 mV. 
 
4.3.3 Size and zeta potential of 16-2-16 gemini surfactants in solutions 
The average aggregate size and the average zeta potential of the gemini surfactants 
are reported in Table-4.5 and illustrated graphically in Figure-4.4. Due to high concentrations 
of the stock solution (1.5 mM, well above the CMC of all the eight surfactants), all the 16-2-
16 gemini surfactants were able to rapidly self-assemble into micelles within the experiment 
conditions.  
From both the size and zeta potential data, it is evident that counterions play a 
significant role on the aggregate hydrodynamic radius and zeta potential for the gemini 
surfactants. Comparing the gemini-halides, 16-2-16-bromide forms smaller aggregates (211 
± 5) with a more homogenous size (as indicated by the lower polydispersity index) than the 
16-2-16-chloride (274 ± 24). This trend followed the CMC pattern of inorganic counterions 
(for example, Br
–
 and Cl
–
) with the sequence mentioned in Hofmeister series based on 
hydrophobicity of inorganic counterions. Both the 16-2-16-Bromide and 16-2-16-Chloride 
aggregates have strong positive zeta potential (ζ) values which indicate that the aggregates 
possess colloidal stability, but also have sufficient positive charge for interaction with and 
compaction of the negatively charged DNA molecules. 
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Table-4.5: Average size, PDI, and Zeta potential for GSs with eight different counterions 
Name of the GS solution 
(1.5 mM) 
Average Size (nm) 
(±SD) 
Average PDI  
Average Zeta (ζ) 
potential (±SD) 
16 – 2 – 16 . 2Br – 211 ± 5 0.23 60 ± 1 
16 – 2 – 16 . 2Cl – 274 ± 24 0.45 53 ± 1 
16 – 2 – 16 . 2AMP – 145 ± 13 0.48 36 ± 3 
16 – 2 – 16 . 2CMP – 110 ± 18 0.37 28 ± 2 
16 – 2 – 16 . 2UMP – 141 ± 13 0.59 27 ± 2 
16 – 2 – 16 . 2GMP – 68 ± 4 0.58 44 ± 5 
16 – 2 – 16 . Tartrate – – 184 ± 29 0.42 110 ± 3 
16 – 2 – 16 . Malate – – 297 ± 45 0.43 22 ± 3 
 
 
Between the 16-2-16-Malate and 16-2-16-Tartrate solutions, the malate counterion 
resulted in surfactant aggregates having the largest size among all 8 counterions investigated, 
with the zeta potential (22 ±3 mV) indicating a less colloidally stable system. Interestingly 
with one additional hydroxyl group in the counterion, 16-2-16-Tartrate formed smaller 
aggregates (185 ± 29 nm), with the largest measured zeta potential (110 ± 3mV) among all 
8 counterions, mainly due to having lower pKa value of tartaric acid than that of malic acid. 
  Lastly, among the four gemini-NMPs, surprisingly the 16-2-16-GMP formed the 
smallest aggregates (68 ± 4 nm) among all the surfactants, despite being the most intractable 
to get solubilized. Among the NMP counterions, the 16-2-16-GMP aggregates had the 
highest ζ value (44 ± 5mV) indicating colloidal stability of the system. These strong positive 
ζ values will also help the researchers to put an assumption on the probable electrostatic 
interactions between the gemini systems and the negatively charged DNA molecules. The 
remaining NMP counterions resulted in 16-2-16 aggregates of comparable sizes. 
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Figure-4.4: Graphical representation of variation of particle sizes (A) and zeta potentials (B) 
with the change of different counterions of 16–2–16 series of gemini surfactants (n = 3, error 
bar = standard deviation). 
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4.3.4 Size and zeta potential of 16–2–16 gemini based nanoparticles 
4.3.4.1 Size and zeta potential of 16–2–16/Plasmid (GP) nanoparticles 
Nanoparticles containing both 16-2-16 and plasmid were prepared following the 
procedure as described in Section 3.2.9.2 of this dissertation. Three different charge ratios of 
16–2–16 to DNA (10:1, 5:1, and 2:1) were used to prepare the G+P nanoparticles; these 
nanoparticles have been prepared and characterized as controls for the complete 16–2–
16/Plasmid/DOPE (GDP) used in the in vitro transfection assays.  
Usually, for a higher charge ratio, more surfactant molecules are available to compact 
the plasmids, which intuitively should result in smaller sized GP aggregates with larger, 
positive, ζ values. In reality, it was very difficult to draw such a conclusive relationship for 
the GP nanoparticles produced using 16-2-16 surfactant with various counterions. From 
Table-4.6, and Figure-4.5 it is clearly manifested that some of the 16-2-16 gemini surfactants 
can produce much smaller sized aggregates after complexation with the plasmids than the 
sizes of the GSs itself. In majority of the cases, the large particles exhibited at the charge 
ratio of 2:1 were likely the result of aggregation upon charge neutralization of 16-2-16 head 
groups and DNA, and in the case of 5:1 and 10:1 charge ratios, subsequent addition of more 
gemini surfactants resulted in a dramatic decrease in particle sizes (except the GP 
nanoparticles formulated from 16-2-16-Malate). 
Here, based on the hydrophobicity of inorganic counterions (for example, Br
–
 and Cl
–
), 16-2-16-Bromide produced smaller aggregates than the 16-2-16-Chloride, and this trend is 
in agreement with the CMC pattern for inorganic counterions as in the Hofmeister series. 
Although no notable pattern, based on either solubility or CMC, was seen on the sizes of the 
gemini-NMP–plasmid aggregates, the aggregate sizes with the gemini-tartrate and gemini-
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malate followed the CMC trend mentioned in the Hofmeister series based on the 
hydrophilicity of organic counterions. Whereas, the zeta potential values (Table-4.6) for the 
GP nanoparticles formed from all the charge ratios were strongly positive, indicating the 
existence of colloidal stability of the nanoparticles formed. The data presented in the tables 
also reinforced that strong electrostatic interactions are responsible to compact the larger 
sized DNA molecule to yield smaller nanoparticles, a crucial factor to obtain desired 
transfections. In all the cases, the PDI values were found by < 0.4 indicating homogeneity of 
the nanoparticles for all the eight GSs, and the SD values were found within ± 20 nm. This is 
mainly due to the presence of strong electrostatic as well as hydrophobic interactions 
between the 16-2-16 gemini surfactants and the negatively charged pNN9 molecules.  
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Table-4.6:  Average sizes, polydispersity indices (PDI) and Zeta potentials (ζ) of 16–2–16 
gemini/Plasmid (GP) nanoparticles 
 
Gemini 
Surfactants 
Nanoparticle 
charge ratio (+/–) 
Size (nm) PDI ζ (mV) 
16–2–16.2Br – G + P (10 :1) 109 ± 9 0.24 43 ± 2 
G + P (5 :1) 225 ± 13 0.31 37 ± 1 
G + P (2 :1) 260 ± 10 0.29 38 ± 2 
 
16–2–16.2Cl – G + P (10 :1) 223 ± 8 0.23 38 ± 1 
G + P (5 :1) 291 ± 11 0.24 33 ± 2 
G + P (2 :1) 325 ± 17 0.40 41 ± 1 
 
16–2–16.Malate – – G + P (10 :1) 211 ± 11 0.21 37 ± 2 
G + P (5 :1) 237 ± 7 0.37 31 ± 1 
G + P (2 :1) 193 ± 12 0.32 43 ± 2 
 
16–2–16.Tartrate – – G + P (10 :1) 112 ± 8 0.31 55 ± 1 
G + P (5 :1) 129 ± 6 0.28 53 ± 2 
G + P (2 :1) 143 ± 14 0.36 45 ± 1 
 
16–2–16.2AMP – G + P (10 :1) 81 ± 12 0.29 33 ± 1 
G + P (5 :1) 106 ± 10 0.23 31 ± 2 
G + P (2 :1) 197 ± 8 0.26 30 ± 1 
 
16–2–16.2CMP – G + P (10 :1) 87 ± 16 0.27 32 ± 1 
G + P (5 :1) 164 ± 9 0.33 30 ± 1 
G + P (2 :1) 209 ± 12 0.31 29 ± 1 
 
16–2–16.2UMP – G + P (10 :1) 116 ± 8 0.36 35 ± 1 
G + P (5 :1) 129 ± 15 0.41 32 ± 1 
G + P (2 :1) 138 ± 11 0.29 31 ± 2 
 
16–2–16.2GMP – G + P (10 :1) 76 ± 10 0.42 36 ± 1 
G + P (5 :1) 112 ± 17 0.36 31 ± 1 
G + P (2 :1) 172 ± 9 0.28 29 ± 1 
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Figure-4.5: Graphical representation of variation of particle sizes (A), and zeta potentials (B) 
of GP nanoparticles at 3 different charge ratios of 16–2–16 gemini to Plasmid with the 
change of different counterions (n = 3, error bar = standard deviation).  
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4.3.4.2 Size and zeta potential of GDP and GD nanoparticles 
 Nanoparticles prepared for the actual transfection of our cells were prepared 
using DOPE as a helper lipid. As described in the introduction of this thesis, the addition of 
DOPE is observed, phenomenalogically to increase the transfection efficiencies of many 
cationic lipids.  This is thought to be due to the fact that DOPE is known to be a fusogenic 
lipid, as well as having a preference for membranes with a high degree of curvature, both of 
which tend to be destabilizing effects (antagonistic effects [190]) when DOPE is incorporated 
into endosomal membranes. Table-4.7 summarizes the average size, polydispersity index and 
zeta potential for the 16-2-16/Plasmid/DOPE (GDP) nanoparticles at three 16-2-16:DNA 
charge ratios, with a 16-2-16:DOPE ratio of 2:5, for the various counterions studied. The 
column charts in Figure-4.6 illustrate the average sizes and zeta potentials of GDP 
nanoparticles at three charge ratios of 16-2-16 : DNA respectively.  
From the evaluation of the particle size variations for lipoplexes across different 
charge ratios, it is assumed that the varying sizes of the GDP lipoplexes, irrespective of post 
incubation time after mixing with DOPE, may be attributed to supercoiled nature of the 
pNN9 plasmids. Because, the supercoiled form of DNA had notable effects on the 
interactions between DNA and gemini surfactant in terms of counterion release during 
lipoplex formation [188, 189]. Literatures suggest that the compact conformation of 
supercoiled CCC pDNA inhibit complete counterion displacement as well as altered 
gemini/DNA interactions leading to subsequent varying size of aggregates [188, 189]. 
Overall, the differences in GDP sizes may be attributed to the existing antagonistic 
interactions between 16-2-16 gemini and DOPE [190] in combination with incomplete 
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counterion release for GP complexes, leading to more prominent DOPE induced instabilities 
that prevented the generation of stable, uniform GDP lipoplex particles. 
 
Table-4.7:  Average sizes, polydispersity indices (PDI) and Zeta potentials (ζ) of 16–2–16 
gemini/Plasmid/DOPE (GDP) nanoparticles 
 
Gemini 
Surfactants 
Nanoparticle 
charge ratio (+/–) 
Size (nm) PDI ζ (mV) 
16–2–16.2Br – G + P + D (10 :1) 521 ± 7 0.47 34 ± 2 
G + P + D (5 :1) 351 ± 15 0.17 47 ± 1 
G + P + D (2 :1) 178 ± 2 0.26 25 ± 1 
 
16–2–16.2Cl – G + P + D (10 :1) 207 ± 31 0.62 39 ± 1 
G + P + D (5 :1) 149 ± 2 0.60 45 ± 4 
G + P + D (2 :1) 228 ± 1 0.38 22 ± 2 
 
16–2–16.Malate – – G + P + D (10 :1) 121 ± 11 0.28 37 ± 1 
G + P + D (5 :1) 111 ± 2 0.53 35 ± 3 
G + P + D (2 :1) 105 ± 1 0.22 29 ± 1 
 
16–2–16.Tartrate – – G + P + D (10 :1) 201 ± 45 0.27 31 ± 1 
G + P + D (5 :1) 172 ± 20 0.35 47 ± 2 
G + P + D (2 :1) 135 ± 30 0.27 24 ± 1 
 
16–2–16.2AMP – G + P + D (10 :1) 83 ± 3 0.32 34 ± 4 
G + P + D (5 :1) 94 ± 3 0.33 55 ± 2 
G + P + D (2 :1) 139 ± 2 0.32 24 ± 1 
 
16–2–16.2CMP – G + P + D (10 :1) 106 ± 4 0.44 49 ± 2 
G + P + D (5 :1) 127 ± 11 0.56 42 ± 2 
G + P + D (2 :1) 427 ± 22 0.47 19 ± 0 
 
16–2–16.2UMP – G + P + D (10 :1) 426 ± 24 0.21 33 ± 4 
G + P + D (5 :1) 92 ± 3 0.35 33 ± 2 
G + P + D (2 :1) 173 ± 7 0.47 23 ± 1 
 
16–2–16.2GMP – G + P + D (10 :1) 810 ± 40 0.63 –33 ± 5 
G + P + D (5 :1) 519 ± 28 0.44 –29 ± 3 
G + P + D (2 :1) 523 ± 22 0.53 –17 ± 1 
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From the table-4.7, it was found that, for 16-2-16-Bromide, 16-2-16-UMP, and 16-2-
16-GMP, the GDP complexes formed are very large (~ 500-1000 nm size range), at the 
charge ratio of 16-2-16 : Plasmid of 10:1; for 16-2-16-GMP being the largest size (810 nm). 
At lower charge ratios (5:1 or 2:1), the transfection mixtures formed acceptable sized 
nanoparticles (~ 80-230 nm range) in terms of relatively higher intracellular uptake and 
efficient gene transfer [191, 192], with the exception of the GDP complexes based of 16-2-
16-bromide, 16-2-16-CMP, and 16-2-16-GMP. Apparently, 16-2-16-Bromide, 16-2-16-
Malate, 16-2-16-Tartrate, and 16-2-16-GMP produced nanoparticles of sizes from larger to 
smaller as the charge ratios decreases from higher (10:1) to lower (2:1). The reverse pattern 
was seen in case of the GDP complexes based on 16-2-16-AMP and 16-2-16-CMP; whereas, 
no conclusive trend was seen for the 16-2-16-Chloride and 16-2-16-UMP. Surprisingly, at 
the charge ratio of 2:1, the GDP transfection mixture based on all the 16-2-16 gemini 
surfactants (except 16-2-16-Chloride, 16-2-16-CMP and 16-2-16-GMP) produced average 
particle sizes of < 200 nm range. Moreover, aggregation of the resulting GDP lipoplexes and 
interference with light scattering measurements, upon charge neutralization, contributed to 
large standard deviations and populations of highly variable particle sizes [110] in majority 
of the 16-2-16 systems. 
It is evident from the table-4.7 that, except for the 16-2-16-GMP, all the other GS 
based transfection complexes possess positive zeta potential values for all the three charge 
ratios. Usually, charged cationic nanoparticles tend to adsorb proteins from the biological 
environment through electrostatic interaction, causing precipitation of the particles, and thus 
often display poor stability in cell culture conditions [193]. Hence, colloidal stability in 
biological environments is a challenging issue in clinical application of any nanoparticle-
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based delivery system due to the large surface area to volume aspect ratio of nanoscale 
materials. For these delivery systems, zeta potential is an important physicochemical 
parameter that influences the stability of nanodispersions [193]. Moderate to extremely 
positive or negative zeta potential values cause larger repulsive forces which prevent time 
dependant aggregation of the particles in resting condition, and thus ensure good stability. 
Thus, in the case of a combined electrostatic and steric stabilization, a minimum zeta 
potential of ± 20 mV is reasonable [193, 194], although the stability range of ± 25 mV is 
widely acceptable, as mentioned in the Zetasizer Nano ZS instrument’s manual. 
Although, among the 16-2-16-NMPs, 16-2-16-GMP possesses the highest positive ζ 
value (+44 mv, Table-4.5), the negative zeta potential values of 16-2-16-GMP based 
transfection complexes here for all the three charge ratios were very surprising and 
unexpected. Although, after compaction of DNA, the reason for the overall negative charge 
of these nanoparticles is unknown, it is predicted that the self-staking nature [123] of this 
gemini molecule itself can cause some sort of morphological changes in the resulting 
nanoparticles which contribute to the possession of the overall negative charges. Now, 
among the three contributing forces for cellular uptake of nanocarriers, namely the 
electrostatic interactions (for oppositely charged surfaces), hydrophobic interaction, and 
hydrophobic hydration [108], the first attractive force has the predominance over the other 
mechanisms for cellular internalization via endocytic pathway, having the biological 
membranes as negatively charged. Hence, considering these phenomena, the resulting 
negative zeta potential values of the 16-2-16-GMP based GDP nanoparticles, render them as 
the less effective candidates for transfection assays due to potential role of predominant 
mechanism for cellular uptake through endocytosis.   
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Figure-4.6: Graphical representation illustrating A) particle sizes, and B) Zeta potentials of 
GDP nanoparticles at 3 different charge ratios of 16-2-16 gemini surfactants : Plasmid (n = 3, 
error bar = standard deviation) 
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Table-4.8 summarizes the average size, polydispersity index and zeta potential for the 
16-2-16/DOPE (GD) nanoparticles for the various counterions studied, where at any of the 
three 16-2-16 : DNA charge ratios, the 16-2-16 : DOPE ratio was always fixed at 2:5. These 
GD complexes served as a negative control for all the in vitro transfection assays. The 
average sizes of the GD complexes were found at approximately 500 nm range for 16-2-16-
Bromide, and at a range of < 300 nm for 16-2-16-Tartrate. Rest of the gemini surfactants 
produced GD particles possessing the average sizes of >> 1000 nm range. Here, the 
propensity for 16-2-16 gemini surfactant to form GD micelles/vesicles of varying sizes 
resulted in the observed high polydispersities as indicated by a PDI value of > ~0.6 in many 
of the 16-2-16/DOPE systems. In addition, the GD nanoparticles also possess strong positive 
charges indicating the colloidal stability of the particles which ultimately have the ability to 
interact with the negatively charged biological membranes.  
 
Table 4.8:  Average sizes, polydispersity indices (PDI) and Zeta potentials (ζ) of 16–2–16 
gemini/DOPE (GD) nanoparticles 
 
Gemini 
Surfactants 
Nanoparticle 
charge ratio (+/–) 
Size (nm) PDI ζ (mV) 
16–2–16.2Br – G + D (2 :5) 577 ± 30 0.65 44 ± 2.4 
16–2–16.2Cl – G + D (2 :5) 1194 ± 138.6 0.64 41 ± 2.8 
16–2–16.Malate – – G + D (2 :5) 1594 ± 102.5 0.74 43 ± 3.0 
16–2–16.Tartrate – – G + D (2 :5) 267 ± 21.8 0.47 41 ± 2.3 
16–2–16.2AMP – G + D (2 :5) 1940 ± 219.8 0.50 41 ± 3.8 
16–2–16.2CMP – G + D (2 :5) 1288 ± 58.4 0.56 39 ± 8.0 
16–2–16.2UMP – G + D (2 :5) 2124 ± 281 0.40 35 ± 5.7 
16–2–16.2GMP – G + D (2 :5) 3392 ± 308 0.22 21 ± 2.8 
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4.4 In vitro transfection assays in OVCAR-3 cells 
4.4.1 Effect of counterions for in vitro transfection assays  
An example of the two way scatter plots obtained from the flow cytometer for the 
controls and treatments are shown in Figure-4.7. Here, the live cells positive for GFP are 
counted along Y axis (green fluorescence), and are differentiated from the dying or dead cells 
positive for propidium iodide (PI) counted along X axis (red fluorescence). The upper right 
quadrant of the plots indicates dying or dead cells expressing GFP (GFP +ve, PI +ve). 
Negative GFP cells i.e. cells not expressing GFP, but still alive (negative PI) are found in 
bottom left quadrant. Live cells expressing GFP are found in the upper left quadrant. All 
dead cells (negative for GFP) found are shown in the bottom right quadrant (PI +ve). 
 
 A            B  
 
 
 
 
 
 C           D  
 
 
 
 
Figure-4.7: An example of two way scatter plots from flow-cytometry indicating A) No GFP 
expression (treated with Opti-MEM media only i.e. no treatment), B) Live cells with GFP 
expression (treated with the control, ‘L’), C) Dying or dead cells with GFP expression 
(treated with G-Br based GDP at 10:1), and D) Dead cells with no GFP expression (treated 
with G-UMP based GDP at 10:1). Each dot represents a single OVCAR-3 cell. 
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4.4.1.1 Effects of counterions on TE: 16-2-16-bromide (G-Br) 
The TE and the normalized cell viabilities for cells treated with different 
nanoparticles based on 16-2-16-bromide are summarized in Table-4.9 and shown graphically 
in Figure-4.8. Here, the highest TE (10 %) was observed for the charge ratio of 10:1 in case 
of DOPE complexed nanoparticles (GDP) whereas the TE for Lipofectamine
TM
 2000 based 
nanoparticles was 10.7 %. Without the helper lipid i.e. the plasmid complexed with only 16-
2-16-bromide (GP), the TE was very close to that observed when DOPE is present, for the 
same charge ratio.  This is in agreement with previous results, which showed that, in a PAM 
212 cell line, the gemini surfactants were capable of transfecting plasmids without the need 
of a helper lipid [106]. The TE for lower charge ratios (5:1 and 2:1) was unexpectedly much 
lower than that of the charge ratio 10:1 and that of Lipofectamine
TM
 2000. Whereas, the sizes 
of GDP particles were much lower for these charge ratio than that of charge ratio 10:1. As 
expected, the results presented in Table-4.9 demonstrate that the negatively charged plasmid, 
in the absence of a delivery vector, is unable to transfect the OVCAR-3 cells.  
 
Table-4.9: TE and cell viability for nanoparticles based on 16-2-16-Br (G), Plasmid (P) and 
Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 10.0 ± 4.9 9.5 ± 2.3 
10.7 ± 0.2 1.3 ± 0.1 5 : 1 4.0 ± 0.3 2.2 ± 0.6 
2 : 1 4.3 ± 0.5 7.1 ± 1.4 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 76.4 ± 14.4 69.8 ± 11.9 
93.9 ± 0.9 105.7 ± 8.6 5 : 1 84.9 ± 2.7 75.9 ± 13.2 
2 : 1 87.5 ± 12.2 93.4 ± 4.3 
 
*Mean ± SD (where, n = 6) 
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Quaternary ammonium groups, which are present in both the 16-2-16 and also in 
Lipofectamine, are toxic, thus transfected cells may show lower viabilities, depending upon 
the composition of the transfection vector. The cell viability for the Lipofectamine was found 
to be 94 %. For the 16-2-16-bromide, cell viability was found to be inversely proportional to 
the charge ratio. The larger the charge ratio, the more gemini used in the formulation, and the 
more the cytotoxic the nanoparticles are. As the plasmids alone are unable to transfect the 
cells no cell death (relative to control) was observed.    
 
A 
 
 
 
 
 
 
 
 B 
 
 
 
 
 
 
 
Figure-4.8: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-Br, L, and P & D only, and B) Normalized viability of cells (compared to no treatment, 
NT) transfected with resulting aggregates from 16-2-16-Br, L, and P & D only (n = 6, error 
bar = standard deviation). 
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4.4.1.2 Effects of counterions on TE: 16-2-16-chloride (G-Cl) 
 The TE and the normalized cell viabilities due to treatment with nanoparticles 
based on 16-2-16-chloride are summarized in Table-4.10 and shown graphically in Figure-
4.9. The nanoparticles produced by this 16-2-16-Cl in the presence of DOPE helper lipids 
(GDP) for the three charge ratios were all within 230 nm range, but the TE was unexpectedly 
much lower than for the Lipofectamine
TM
 2000 formulation (12.4 %). The lowest TE found 
for the complete 16-2-16-Cl/DOPE/Plasmid (GDP) complex was in case of charge ratio 10:1 
where only 1.7 % TE was observed. As the charge ratios were decreased, increased TE was 
seen for the GDP complexes but none at a level comparable to the TE for Lipofectamine 
treated cells. As for 16-2-16-Cl, nanoparticles formed without the DOPE (GP), exhibited 
transfection, but at substantially lower levels than for the complete GDP nanoparticles. 
 
Table-4.10: TE and cell viability by nanoparticles based on 16-2-16-Cl
 
(G), Plasmid (P) and 
Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 1.7 ± 0.7 1.9 ± 0.4 
12.4 ± 3.8 1.1 ± 0.2 5 : 1 3.7 ± 0.3 2.7 ± 0.0 
2 : 1 8.1 ± 1.3 6.2 ± 1.8 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 69.9 ± 0.3 60.1 ± 10.9 
89.2 ± 2.4 99.7 ± 0.5 5 : 1 90.1 ± 0.6 90.2 ± 2.1 
2 : 1 94.8 ± 3.5 96.3 ± 2.9 
 
*Mean ± SD (where, n = 6) 
 
  The cell viabilities for OVCAR-3 cells treated with 16-2-16-Cl formulations 
were comparable to those observed for Lipofectamine, for charge ratios 5:1 and 2:1. For the 
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charge ratio 10:1, cell viability was reduced (69.9 %), although the TE was insignificant.  
Evaluation of the combined TE and cell viability results for 16-2-16-Cl suggest it is less toxic 
than the 16-2-16-Br, but also less efficient as a transfection vector. 
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Figure-4.9: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-Cl, L, and P & D only, and B) Normalized viability of cells (compared to no treatment, 
NT) transfected with resulting aggregates from 16-2-16-Cl, L, and P & D only (n = 6, error 
bar = standard deviation). 
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4.4.1.3 Effects of counterions on TE: 16-2-16-malate (G-malate) 
 The TE and the normalized cell viabilities due to treatment with nanoparticles 
based on 16-2-16-malate are summarized in Table-4.11 and shown graphically in Figure-
4.10. The GDP transfection complexes for 16-2-16-malate showed comparable TE to that of 
Lipofectamine and 16-2-16 Cl for the charge ratio of 2:1, for which particle size was 
approximately 230 nm. For the other charge ratios (10:1 and 5:1), the TE was low for the 
GDP complexes. In the absence of DOPE all the GP complexes exhibited TE greater than 
that for GDP nanoparticles at all three charge ratios. The highest TE for 16-2-16-malate was 
observed for the GP complex (11.7 %). Here, the use of helper lipid seemed to decrease the 
ability of 16-2-16-malate to transfect the OVCAR-3 cells probably due to lower (DOPE 
mediated) endosomal escape. From the resulting sizes, it is evident that the 16-2-16-
malate/Plasmid/DOPE (GDP) formed complexes in a much compact manner compared to the 
sizes of GDP complexes based on 16-2-16-halides. Probably, the transition of DOPE from 
lamellar (L
C
α) to inverted hexagonal phase (H
C
II) was not sufficient enough to release the 
G+P complexes from the GDP aggregates to enhance the resulting transfection.   
 
Table-4.11: TE and cell viability by nanoparticles based on 16-2-16-malate (G), Plasmid (P) 
and Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 6.0 ± 1.7 11.7 ± 6.0 
9.9 ± 0.2 1.8 ± 0.1 5 : 1 4.7 ± 2.0 4.8 ± 1.6 
2 : 1 7.9 ± 0.5 9.5 ± 0.4 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 48.0 ± 4.3 52.3 ± 14.3 
82.1 ± 2.5 105.8 ± 3.0 5 : 1 58.7 ± 2.2 73.4 ± 7.9 
2 : 1 98.3 ± 4.3 95.6 ± 2.2 
 
*Mean ± SD (where, n = 6) 
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 From the cell viability results, it can be seen that the 16-2-16-malate counterion is 
apparently more toxic at increased charge ratios, and more toxic than the 16-2-16-halide 
surfactants. Aside from the presence of quaternary ammonium groups in the 16-2-16-malate, 
the elevated cytotoxicity for this vector is probably due to alteration of cytosolic pH as well 
as osmotic pressure, and due to the presence of toxic metabolites as a result of intracellular 
metabolism of the exogenous molecules (malate ions).  
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Figure-4.10: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-malate, L and P & D only, and B) Normalized viability of cells (compared to no 
treatment, NT) transfected with resulting aggregates from 16-2-16-malate, L, and P & D only 
(n = 6, error bar = standard deviation). 
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4.4.1.4 Effects of counterions on TE: 16-2-16-tartrate (G-tartrate) 
 The TE and the normalized cell viabilities due to treatment with different 
nanoparticles based on 16-2-16-tartrate are summarized in Table-4.12 and shown graphically 
in Figure-4.11. The nanoparticles produced by this 16-2-16-tartrate in the presence of DOPE 
helper lipids (GDP) for the three charge ratios were all ≤ 200 nm range, but the TE was much 
lower than for the Lipofectamine
TM
 2000 formulation (11.0 %). Here, the lowest TE found 
for the GDP complex was in case of charge ratio 10:1 where only 4.7 % TE was observed. 
As the charge ratios were decreased and thus, as the resulting particle sizes decreased, minor 
increase in the TE was seen for the GDP complexes; but none at a level comparable to the TE 
for Lipofectamine treated cells. For this 16-2-16-tartrate, the nanoparticles formulated 
without the DOPE lipid showed transfection which was lower than for the complete GDP 
nanoparticles in case of the lower charge ratios (5:1 & 2:1). Again, as expected, the results 
presented in Table-4.18 demonstrate that the negatively charged plasmid, in the absence of a 
delivery vector, is unable to transfect the OVCAR-3 cells.    
 
Table-4.12: TE and cell viability by nanoparticles based on 16-2-16-tartrate
 
(G), Plasmid (P) 
and Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 4.7 ± 0.4 5.7 ± 0.8 
11.0 ± 1.3 2.4 ± 0.1 5 : 1 5.8 ± 0.1 4.8 ± 0.0 
2 : 1 6.8 ± 0.8 6.3 ± 0.5 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 55.7 ± 0.4 51.6 ± 1.2 
83.4 ± 1.8 101.4 ± 0.6 5 : 1 63.6 ± 0.7 73.6 ± 5.3 
2 : 1 96.9 ± 2.9 97.4 ± 2.6 
 
*Mean ± SD (where, n = 6) 
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 The cell viabilities of OVCAR-3 cells transfected with 16-2-16-tartrate nanoparticle 
formulation were comparable to those observed for Lipofectamine
TM
 (83.4 %), for the charge 
ratio 2:1 only. It is evident from the cell viability data that the tartrate counterions of the 16-
2-16-Tartrate vectors are toxic at higher charge ratios, and more toxic than the 16-2-16-halide 
vectors. Similar trend of viabilities were seen in case of GP nanoparticles. Here the overall 
pH of the complete nanoparticles (GDP complexes) may be a contributing factor for 
significant alteration of cytosolic pH, and thus cytotoxicity. As mentioned earlier, the pH of 
16-2-16-Tartrate vector itself was found strongly acidic (3.8).  
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 B 
 
 
 
 
 
Figure-4.11: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-tartrate, L, and P & D only, and B) Normalized viability of cells (compared to no 
treatment, NT) transfected with resulting aggregates from 16-2-16-tartrate, L, and P & D 
only (n = 6, error bar = standard deviation). 
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4.4.1.5 Effects of counterions on TE: 16-2-16-AMP (G-AMP) 
 The TE and the normalized cell viabilities due to treatment with different 
nanoparticles based on 16-2-16-AMP are summarized in Table-4.13 and graphically 
represented in Figure-4.12. Surprisingly, the TE of the GDP nanoparticles for 16-2-16-AMP 
was moderate (8.9 %) at the charge ratio of 10:1 which was even higher than the TE for 
Lipofectamine
TM
 2000 (8.3 %), and also higher than the TE  seen in case of 16-2-16-Cl, 16-
2-16-malate and 16-2-16-tartrate GDP systems at any charge ratios. Most interestingly, the 
TE for the GP nanoparticles were significantly higher for charge ratios 10:1 & 5:1, showing 
highest TE (14.4%) at charge ratio of 10:1. In this case, the TE of the GP nanoparticles 
exhibited a decreasing trend, as the charge ratios decreases. Like the 16-2-16-malate systems, 
for the GDP nanoparticles based on 16-2-16-AMP, the use of helper lipid seemed to decrease 
the ability of 16-2-16-AMP to transfect the OVCAR-3 cells probably due to the similar 
reason mentioned in the section 4.4.1.3.  
 
Table-4.13: TE and cell viability by nanoparticles based on 16-2-16-AMP
 
(G), Plasmid (P) 
and Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 8.9 ± 1.5 14.4 ± 6.9 
8.3 ± 0.6 3.3 ± 1.8 5 : 1 7.1 ± 0.4 9.5 ± 0.7 
2 : 1 8.1 ± 0.9 7.9 ± 1.7 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 48.0 ± 2.9 49.2 ± 19.0 
64.7 ± 7.3 91.5 ± 0.0 5 : 1 51.8 ± 0.1 55.6 ± 25.6 
2 : 1 84.7 ± 3.1 86.4 ± 11.4 
 
*Mean ± SD (where, n = 6) 
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 From the cell viability results it can be seen that the GDP complexes based on 16-2-
16-AMP surfactants, are quantitatively similar cytotoxic as seen from the 16-2-16-malate 
surfactants and increased cytotoxicity was seen at higher charge ratios. Similar trend was also 
seen in the case of GP nanoparticles. For both of the nanoparticle systems (GDP & GP), the 
16-2-16-AMP was found less toxic than those of 16-2-16-tartrate, but significantly more 
toxic when compared to those of 16-2-16-halides. This increased cytotoxicity may be 
attributed due to the fact of cytosolic pH and osmotic pressure alteration and presence of 
toxic metabolites due to intracellular metabolism of the exogenous ions (AMP) in cytosol.  
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Figure-4.12: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-AMP, L, and P & D only, and B) Normalized viability of cells (compared to no 
treatment, NT) transfected with resulting aggregates from 16-2-16-AMP, L, and P & D only 
(n = 6, error bar = standard deviation). 
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4.4.1.6 Effects of counterions on TE: 16-2-16-CMP (G-CMP) 
 The TE and the normalized cell viabilities due to treatment with different 
nanoparticles based on 16-2-16-CMP are summarized in Table-4.14 and shown graphically 
in Figure-4.13. The nanoparticles produced by this 16-2-16-CMP in presence of DOPE 
helper lipids (GDP) for the charge ratios of 10:1 and 5:1 were < 200 nm range, but the TE at 
5:1 was unexpectedly much lower (3.6 %) than for the Lipofectamine
TM
 2000 formulation 
(12.6 %). The highest TE found for the GDP complexes  was in case of charge ratio 10:1, 
whereas, the lowest was observed is the case of charge ratio 2:1, probably due to low cellular 
uptake of the large sized GDP aggregates (427 nm). Similar trend of TEs were seen in the 
case of GP nanoparticles, but were significantly lower than those of the GDP complexes. As 
the charge ratios were increased, increased TE was seen for the GDP complexes but none at a 
level comparable to the TE for Lipofectamine treated cells. Here, the usage of helper lipid 
seemed to increase the ability of 16-2-16-CMP to transfect the OVCAR-3 cells.   
 
Table-4.14: TE and cell viability by nanoparticles based on 16-2-16-CMP
 
(G), Plasmid (P) 
and Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 7.3 ± 0.2 5.4 ± 0.5 
12.6 ± 0.3 1.5 ± 0.4 5 : 1 3.6 ± 0.1 3.3 ± 0.2 
2 : 1 2.2 ± 1.0 2.4 ± 0.2 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 70.5 ± 6.5 61.9 ± 4.9 
83.8 ± 3.0 109.9 ± 4.7 5 : 1 61.5 ± 18.9 45.5 ± 0.3 
2 : 1 103.3 ± 12.5 90.8 ± 13.5 
 
*Mean ± SD (where, n = 6) 
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 The cell viability for the GDP complexes of this 16-2-16-CMP vector was 
moderate in the case of charge ratios 10:1 & 5:1, but lower than the cell viability for 
Lipofectamine (83.8%). The cytotoxicity seemed higher at increased charge ratios and this 
16-2-16-CMP was found less toxic than those of 16-2-16-malate, 16-2-16-tartrate, and 16-2-
16-AMP at any charge ratio. Almost no cell death was found for the GDP complexes of 16-
2-16-CMP in case of charge ratio 2:1, compared to control, and again this is probably due to 
very low cellular uptake of the GDP particles having the mean size of 427 nm at that charge 
ratio.  
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Figure-4.13: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-CMP, L, and P & D only, and B) Normalized viability of cells (compared to no 
treatment, NT) transfected with resulting aggregates from 16-2-16-CMP, L, and P & D only 
(n = 6, error bar = standard deviation). 
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4.4.1.7 Effects of counterions on TE: 16-2-16-UMP (G-UMP) 
 The TE and the normalized cell viabilities due to treatment with different 
nanoparticles based on 16-2-16-UMP are summarized in Table-4.15 and shown graphically 
in Figure-4.14. At the charge ratio of 10:1, the GDP complexes formed by 16-2-16-UMP was 
large (426 nm), but unexpectedly, significantly higher TE was seen compared to that of 16-2-
16-Cl, 16-2-16-malate, and 16-2-16-tartrate. Surprisingly, at charge ratio 5:1, the observed 
TE suddenly decreased (also in the case of 16-2-16-AMP), although the resulting GDP 
particles were of lowest size (92 nm) among all the three charge ratios. As the charge ratios 
were decreased to 2:1, increased TE was seen for the GDP complexes but none at a level 
comparable to the highest TE for Lipofectamine (14.5 %) treated cells. In case of GP 
nanoparticles, similar and comparable TE was seen except the fact that, the use of helper 
lipid for the charge ratio 10:1 seemed to decrease the ability of 16-2-16-UMP to transfect the 
OVCAR-3 cells.  
 
Table-4.15: TE and cell viability by nanoparticles based on 16-2-16-UMP (G), Plasmid (P) 
and Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 7.4 ± 0.3 8.0 ± 0.7 
14.5 ± 0.3 2.5 ± 0.2 5 : 1 4.8 ± 0.3 3.6 ± 0.1 
2 : 1 8.8 ± 0.2 8.4 ± 0.2 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 38.9 ± 1.9 34.4 ± 1.7 
78.5 ± 2.6 101.7 ±2.9 5 : 1 58.6 ± 2.8 52.2 ± 0.1 
2 : 1 92.2 ± 1.1 94.2 ± 1.0 
 
*Mean ± SD (where, n = 6) 
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 From the cell viability results, it can be seen that the nanoparticles for both the 
systems (GDP & GP) based on 16-2-16-UMP vectors are apparently more toxic at increased 
charge ratios, and the most toxic than all the 16-2-16 gemini vectors discussed so far. This is 
due to the fact that the UMP counterion of 16-2-16-UMP system contains uracil moiety and 
these uracil moieties (such as in 5-Fluoro Uracil, 5-FU) showed tumor selective cytotoxicity 
[195, 196].  Again, this extreme cytotoxicity may also be partly attributed to the alteration of 
cytosolic pH and osmotic pressure, as the pH of the 16-2-16-UMP alone was found to be 
most acidic (3.1) among all the 16-2-16 gemini vectors studied.  
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Figure-4.14: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-UMP, L, and P & D only, and B) Normalized viability of cells (compared to no 
treatment, NT) transfected with resulting aggregates from 16-2-16-UMP, L, and P & D only 
(n = 6, error bar = standard deviation). 
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4.4.1.8 Effects of counterions on TE: 16-2-16-GMP (G-GMP) 
 The TE and the normalized cell viabilities due to treatment with different 
nanoparticles based on 16-2-16-GMP are summarized in Table-4.16 and shown graphically 
in Figure-4.15. From the zeta potential characterization results, it was seen that the GDP 
complexes based on gemini-GMP have a net negative surface charge and was predicted that 
these high –ve ζ values (especially in the case of charge ratios 10:1 and 5:1) will render the 
GDP complexes as the lowest effective candidates to transfect the OVCAR-3 cells. 
Surprisingly, the GDP complexes based on 16-2-16-GMP showed TE to some extent, with 
the highest TE seen at the charge ratio of 10:1, although the resulting GDP complex size was 
approximately 1 μm (810 nm) at that charge ratio. As the charge ratios were decreased, this 
16-2-16-GMP vector produced GDP complexes of ~ 530 nm size range, and decreased TE 
was seen for the GDP complexes but none at a level comparable to the highest TE for 
Lipofectamine
TM
 2000 (10.7 %) treated cells. In case of GP nanoparticles, similar trend of 
TE was seen based on charge ratios except the fact that, the use of helper lipid for the charge 
ratio 2:1 seemed to decrease the ability of 16-2-16-GMP to transfect the OVCAR-3 cells. 
 
Table-4.16: TE and cell viability by nanoparticles based on 16-2-16-GMP (G), Plasmid (P) 
and Lipofectamine (L): 
 
Parameters 
Charge 
Ratio  
(GS : P) 
Nanoparticle formulations 
Transfection complexes Controls 
G+P+D G+P L+P P 
Percentage of 
transfection*  
(GFP + ve) 
10 : 1 5.4 ± 1.0 4.4 ± 0.1 
10.7 ± 0.2 1.8 ± 0.6 5 : 1 3.5 ± 0.1 3.1 ± 1.2 
2 : 1 3.4 ± 0.1 4.1 ± 0.4 
Percentage of  
cell viability* 
(Normalized) 
10 : 1 42.9 ± 0.1 29.5 ± 1.9 
71.8 ± 0.8 94.3 ± 4.2 5 : 1 51.3 ± 0.7 56.8 ± 5.3 
2 : 1 86.6 ± 1.6 88.8 ± 0.1 
 
*Mean ± SD (where, n = 6) 
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 The cell viability for OVCAR-3 cells treated with 16-2-16-GMP nanoparticles 
(both GDP & GP) were comparable to those observed for the 16-2-16-AMP systems, for all 
the three charge ratios. The results suggest that 16-2-16-GMP vector is more toxic at 
increased charge ratios, and viability due to treatment with GDP/GP was found higher than 
that of Lipofectamine (71.8 %) at the charge ratio of 2:1.  
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Figure-4.15: Graphical representation illustrating A) TE of the resulting aggregates from 16-
2-16-GMP, L, and P & D only, and B) Normalized viability of cells (compared to no 
treatment, NT) transfected with resulting aggregates from 16-2-16-GMP, L, and P & D only 
(n = 6, error bar = standard deviation). 
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4.4.2 Summary of the effects of counterions on TE 
The following table (Table-4.17) summarizes the transfection efficiencies (TE) and 
cell viabilities (%viability) for nanoparticles formed from all eight 16-2-16 surfactants, in 
combination with plasmid alone (GP formulations) or plasmid and DOPE (GDP 
formulations). Although no generalized relation or pattern is observed, overall, the TE was 
found to be moderate at the lowest charge ratio (2:1), as the GDP particle sizes formed from 
all the GSs was within nanoparticle range (~500 nm) at that charge ratio. In few cases, the 
TE was exceptionally higher at the charge ratio (10:1).  
Particle size significantly affects the cellular and tissue uptake of nanoparticles in 
non-viral transfection formulations [197]. In one of the studies, Manisha et al. reported that 
the polylactic-polyglycolic acid co-polymer (PLGA 50:50) nanoparticles of 100 nm sizes 
showed 2.5 fold greater uptake compared to 1 μm particles, and 6 fold higher uptake 
compared to 10 μm microparticles in human epithelial colorectal adenocarcinoma (Caco-2) 
cell line [198]. Similar trend of results were attained when these formulations of nano- and 
microparticles were tested in a rat in situ intestinal loop model. The efficiency of cellular 
uptake of 100 nm size particles was seen 15–250 fold greater than larger size (1 and 10 μm) 
microparticles [199]. Moreover, Prabha et al. (2002) reported that smaller sized nanoparticles 
can give rise to a 27-fold higher TE (analysed by luciferase protein levels) than that of the 
larger-sized nanoparticles, in COS-7 cells [197]. But in our study, the impact of particle size 
was not that prominent as few of the gemini surfactants, namely 16-2-16-bromide, 16-2-16-
CMP, 16-2-16-UMP, and 16-2-16-GMP formed particles of ~500 nm sizes (for 16-2-16-
GMP, particle sizes was > 500 nm) at either 10:1 or 2:1 charge ratios, while exerting 
moderate TE at the charge ratio of 10:1.  
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Table 4.17:  Summary of transfection efficiencies (TEs) and cell viabilities (% viable) due to 
treatment with GDP and GP nanoparticles based on all 16-2-16.X surfactants 
 
Formulation 
TE* (%) % Viable* 
10:1 5:1 2:1 10:1 5:1 2:1 
Lipofectamine** 11.3 ± 0.9 86.6 ± 2.7 
GDP (Br) 10.0 ± 4.9 4.0 ± 0.3 4.3 ± 0.3 76.4 ± 14.4 84.9 ± 2.7 87.5 ± 12.2 
GP (Br) 9.5 ± 2.3 2.2 ± 0.6 7.1 ± 1.4 69.8 ± 11.9 75.9 ± 13.2 93.4 ± 4.3 
       
GDP (Cl) 1.7 ± 0.7 3.7 ± 0.3 8.1 ± 1.3 69.9 ± 0.3 90.1 ± 0.6 94.8 ± 3.5 
GP (Cl) 1.9 ± 0.4 2.7 ± 0.0 6.2 ± 1.8 60.1 ± 10.9 90.2 ± 2.1 96.3 ± 2.9 
       
GDP (Malate) 6.0 ± 1.7 4.7 ± 2.0 7.9 ± 0.5 48.0 ± 4.3 58.7 ± 2.2 98.3 ± 4.3 
GP (Malate) 11.7 ± 6.0 4.8 ± 1.6 9.5 ± 0.4 52.3 ± 14.3 73.4 ± 7.9 95.6 ± 2.2 
       
GDP (Tartrate) 4.7 ± 0.4 5.8 ± 0.1 6.8 ± 0.8 55.7 ± 0.4 63.6 ± 0.7 96.9 ± 2.9 
GP (Tartrate) 5.7 ± 0.8 4.8 ± 0.0 6.3 ± 0.5 51.6 ± 1.2 73.6 ± 5.3 97.4 ± 2.6 
       
GDP (AMP) 8.9 ± 1.5 7.1 ± 0.4 8.1 ± 0.9 48.0 ± 2.9 51.8 ± 0.1 84.7 ± 3.1 
GP (AMP) 14.4 ± 6.9 9.5 ± 0.7 7.9 ± 1.7 49.2 ± 19.0 55.6 ± 25.6 86.4 ± 11.4 
       
GDP (CMP) 7.3 ± 0.2 3.6 ± 0.1 2.2 ± 1.0 70.5 ± 6.5 61.5 ± 18.9 103.3 ± 12.5 
GP (CMP) 5.4 ± 0.5 3.3 ± 0.2 2.4 ± 0.2 61.9 ± 4.9 45.5 ± 0.3 90.8 ± 13.5 
       
GDP (UMP) 7.4 ± 0.3 4.8 ± 0.3 8.8 ± 0.2 38.9 ± 1.9 58.6 ± 2.8 92.2 ± 1.1 
GP (UMP) 8.0 ± 0.7 3.6 ± 0.1 8.4 ± 0.2 34.4 ± 1.7 52.2 ± 0.1 94.2 ± 1.0 
       
GDP (GMP) 5.4 ± 1.0 3.5 ± 0.1 3.4 ± 0.1 42.9 ± 0.1 51.3 ± 0.7 86.6 ± 1.6 
GP (GMP) 4.4 ± 0.1 3.1 ± 1.2 4.1 ± 0.4 29.5 ± 1.9 56.8 ± 5.3 88.8 ± 0.1 
 
*Mean ± SD (where, n = 6), **Mean ± SD (where, n = 16) 
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In general, between the 16-2-16-halide, the 16-2-16-bromide showed better TE at 
10:1 but, the 16-2-16-chloride showed moderate TE at 2:1. Between the 16-2-16-
carboxylates, the GDP particles of based on both the 16-2-16–tartrate and 16-2-16–malate 
showed better TE at 2:1. Lastly, among the 16-2-16-NMPs, the 16-2-16-AMP showed 
moderate TE at 10:1 and 2:1; the 16-2-16-CMP showed good TE at 10:1; the 16-2-16-UMP 
showed TE at 10:1 and 2:1; and gemini-GMP showed poor TE at 10:1. Except in the cases of 
16-2-16-Br, 16-2-16-AMP, 16-2-16-CMP, and 16-2-16-GMP, the TE was found to increase 
with the progression of charge ratios from higher (10:1) to lower (2:1). These results were in 
agreement with previous reports by Wang at el. [145] where it was reported that TE in 
OVCAR-3 cell line decreased with increasing charge ratios. 
Besides, irrespective of charge ratios, 16-2-16-halides (bromide) and 16-2-16-NMPs 
(except 16-2-16-GMP) are more efficient vectors to transfect OVCAR-3 cells, compared to 
the 16-2-16-malate/tartrate vectors. In relation to DOPE, the TE due to GP nanoparticles 
were found significantly higher than the TE due to GDP particles of 16-2-16-malate (dGP = 
211 nm & dGDP = 121 nm; where d = size/diameter) and 16-2-16-AMP (dGP = 81 nm & dGDP 
= 83 nm; where d = size/diameter) at the charge ratio of 10:1, and thus, inferred that the role 
of DOPE lipid was ineffectual for both of these cases. As discussed earlier, the probable 
reason for this phenomena was during endosomal escape, the release of the GP complexes 
from the GDP complexes was not sufficient enough, upon transition of DOPE from lamellar 
(L
C
α) to inverted hexagonal phase (H
C
II).  
The GP complexes were found to consistently exhibit low TEs compared to GDP 
lipoplexes (except few cases as discussed above) most likely due to their inability to undergo 
structural polymorphisms, for endosomal escape and DNA release, in absence of DOPE 
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[200]. From our results, it is also evident that, the TE of the Lipofectamine
TM
 2000 (positive 
control) was drastically lower than previous reports (11.3 % vs 32.2 %) [94, 145], which may 
be attributed to cellular senescence caused by high passage number (12-18), during which 
transfections took place. Further studies, using OVCAR-3 as well as other cell lines, may 
justify the complete analysis of the differences in TE attained from lipoplexes generated from 
16-2-16 gemini systems. 
For all the 16-2-16-gemini systems, the normalized cell viability was approximately 
95 % on average (compared to control) in the case of charge ratio of 2:1 and more toxicity 
was seen as the charge ratios increased in general. Eventually, the evaluation of the combined 
TE and cell viability results for all the 16-2-16-gemini surfactants suggest that, irrespective 
of charge ratio, the 16-2-16-bromide (halide family of counterion) is the lowest toxic in 
nature, but also the most efficient as a transfection vector among the eight 16-2-16-gemini 
vectors studied in this project. 
The following figures (Figure-4.16 & Figure-4.17) depict the comparative summary 
of TE & cell viability due to treatment with (GDP & GP) nanoparticles respectively, based 
on all the 16-2-16 series of gemini surfactants with different counterions.  
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Figure-4.16: Graphical representation illustrating TE of particles, based on 16-2-16 series of 
gemini surfactants associated with eight different counterions, for all the three charge ratios: 
A) For GDP nanoparticles, and B) For GP nanoparticles (n = 6, error bar = standard 
deviation) 
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Figure-4.17: Variation of OVCAR-3 percentage cell viability at three different charge ratios 
when treated with A) GDP nanoparticles, and B) GP nanoparticles, generated from 16-2-16 
series of gemini associated with eight different counterions (n = 6, error bar = standard 
deviation).
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5. Summary and Future Directions 
 We report the results of the systematic investigation of the effect of associated 
counterions on the micellization of a novel series of quaternary ammonium 16-2-16 gemini 
surfactants, in aqueous solution. Our focus regarding the solution properties, aggregation, 
and micellization of GSs, clearly suggests that ionic hydration, ion polarizability, 
hydrophobic interactions, counterion dissociation, and intra/inter-molecular hydrogen bonds 
cooperatively influence the micellization process and the propensity of the counterions to 
form ion pairs with the oppositely charged head groups of gemini in solution. The results of 
our study provide new insight to understand the diversified effects of counterions on the 
intriguing properties of these novel and green surfactants “The Gemini”. For all the anions, it 
was found that, hydrophilicity, polarizability, and hydration numbers of the ions are the 
dominant factors determining micellization.  
In summary, the critical micellar concentration (CMC), degree of micellization (α), as 
well as degree of binding of counterions to the micelles (β) and other surface properties such 
as surface excess concentration (Γmax), surface pressure, and minimum area per molecule 
(Amin) at the air/water interface of these bis-cationic dimeric GSs strongly depend on the 
associated counterions of the respective gemini.  Moreover, from our study it was revealed 
that, the counterions have massive impact on the solubilities and the Krafft temperatures of 
the individual gemini, mainly due to electrostatic interactions as described earlier. As a part 
of unique behavior in solution, counterions also play a role for change in density and 
viscosity due to their micellar packing volume and matrix type aggregation in aqueous 
solution. Lastly, the foam stability of the gemini is governed by the stable micellar packing in 
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the adsorbed foam lamellae, and the higher the micellar stability, the greater is the foam 
stability. 
For this project, to investigate the TE we are reporting the transfection ability of 16-2-
16 series of GSs associated with different counterions among which the transfectability of 
those GS with organic counterions are being reported for the first time ever. Considering 
both the average TE and cytotoxicity, from our investigation it was revealed that the optimal 
charge ratio of GSs to DNA for good to moderate transfection was found to be 2:1. 
Furthermore, the particle size characterization of the GDP transfection complexes indicates 
that particles generated from any of the 16-2-16 gemini surfactants at any charge ratios are 
within submicron sized. None of the associated counterions showed significantly better TEs 
than that of the commercially available lipid based reagent Lipofectamine
TM
 2000. By 
changing the associated counterions, our primary goal was to develop efficient GSs as 
transgene delivery vectors for ovarian cancer gene therapy. With the disagreement as we 
hypothesized, the change in counterions for GSs as a parameter for vector design did not 
enhance the TE in OVCAR-3 cells at all in comparison to that of Lipofectamine (11.3 ± 0.9) , 
but we found moderate transfection ability for few 16-2-16 gemini associated with few 
counterions as discussed in the results section. In terms of cytotoxicity, the counterions 
seemed well tolerated on average by the cells, eliminating the considerations of effect of 
mechanical rigors (such as aggressive handling, unexpected contaminations, pH effects of the 
overall transfection complexes) on cytotoxicity. Our results proved and reinforced that 
smaller sized particles (i.e. < 200 nm) are not a ‘mandatory’ requirement for transfection in 
vitro in OVCAR-3 cell line, and our finding is also consistent with results reported by 
Foldvari et al. [201]. However, these micro-sized particles would not be the good candidates 
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for in vivo TE studies, because larger particles may be rapidly degraded by phagocytic cells 
and the reticuloendothelial systems (RES) as mentioned in the “Introduction” section.  
Although we report the morphology (see “Appendix” section) of the GSs only based 
on CPP values, this project could be expanded using TEM or atomic force microscopy 
(AFM) imaging to investigate the effect of change in the associated counterions on aggregate 
morphology of these novel GSs, considering the importance of micellar morphology. Also, 
this study could be expanded to investigate the aggregation number of the resulting micelles 
of the GSs as part of important physical characterization data using fluorescence quenching 
(FQ) technique. 
The interaction between the gemini molecules and DNA is another potential study to 
be explored. Since the GSs associated with different counterions are designed for DNA 
delivery to be considered as efficient vectors, it would be questionable if the existing 
interactions of the cationic GSs and the polyelectrolyte DNA is not studied to reveal how the 
solution properties of GSs are moulded by the addition of DNA and also the effect of 
changing the counterions on the this GS-DNA interaction. Thus this project could be 
expanded to investigate this through the application of experimental tools like the isothermal 
titration calorimetry (ITC) for thermodynamic investigations & critical aggregate 
concentration (CAC) determination, and Brewster angle microscopy (BAM) for pre-/post 
images of the interactions.  
In terms of transfection, future studies using animal models should be explored for all 
the charge ratios to investigate the actual resulting influence in reality on gene delivery. 
Additionally, stability of transfection complexes may be increased by modifying transfection 
complexes with the attachment of polyethylene glycol (PEG) to the GSs since no studies 
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involving PEGylation of GSs based DNA delivery have been carried out. Apart from this 
PEG conjugation approach, pluronic co-polymer or functionalized pluronics with 
biodegradable moieties (such as PAGA i.e. poly-[α-(4-aminobutyl)-L-glycolic acid]) based 
gene delivery could also be considered to be studied which has enormous potential for 
efficient gene delivery [202]. To battle cancers via gene therapy approach, cell-specific 
targeting is one of the crucial considerations which could be a paramount sector for further 
research. Thus, another fact to consider for this project in future will be the modification of 
GSs by attaching a targeting group (i.e. folate if the treatment is for OCs) which will allow 
increased cellular uptake and cell specificity, when transfection studies will be done with 
these GSs conjugated with a target ligand both at in vitro and in vivo situations. 
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Appendix 
A-1.1: Atomic details and 
1
H NMR spectral analysis of 1-halohexadecane: 
 
The structure of the 1-halohexadecane (Cetyl halide) is as following –  
 
CH3 – CH2 – (CH2)12 – CH2 – 
+
CH2 – X
–
 
Atomic details: 
Total Carbon,  (C)  = 16  
Total Hydrogen, (H)  = 33  
Total Halide, (X
–
) = 1 (X
–
 = Bromide or Chloride) 
 
      C 
 
X 
 
 
             
 
                     A 
    E          D                B 
 
Figure-A-1.1: Assignment of protons in the 1-Halohexadecane structure used in the 
interpretation of 
1
H NMR spectra.  
 
Category / Name of the Proton Total number of proton for that category 
A 3 
B 2 
C 24 
D 2 
E 2 
TOTAL for all category 33 Protons 
 
 
 
 
 
 
 
 
 
 CDCl3    E  D  B C A 
 
Figure-A-1.2: Identification of 
1
H NMR peaks of protons of 1-halohexadecane (in CDCl3)  
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A-1.3: Atomic details and 
1
H NMR spectral analysis of TMEDA:  
 
The structure of the N,N,N′,N′-tetra–methyl–ethylene–1,2-di-amine (TMEDA) is as 
following –  
 
(CH3)2N – CH2 –CH2 – N(CH3)2 
 
Atomic details:       A 
Total Carbon,  (C)  = 6 
Total Hydrogen, (H)  = 16  
Total Nitrogen, (N) = 2 
 
           B         B 
 
       
 
A 
 
Figure-A-1.3: Assignment of protons in the N,N,N′,N′-Tetramethylethylene–1,2-diamine 
(TMEDA) structure used in the interpretation of 
1
H NMR spectra.   
 
Category / Name of the Proton Total number of proton for that category 
A 4 
B 12 
TOTAL for all category 16 Protons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-A-1.4: Identification of 
1
H NMR peaks of protons of TMEDA (in CDCl3) 
APPENDIX 
135 
 
A-1.3: Atomic details and 
1
H NMR spectral analysis of Tartaric Acid:  
 
The structure of the Tartaric Acid (MW = 150.01; Molecular formula: C4H6O6) is –  
 
        P 
Atomic details: 
Total Carbon,  (C)  = 4    R  R 
Total Hydrogen, (H)  = 6 
Total oxygen,  (O) = 6 
       Q           
 Q 
 
 
 
 
         P 
Figure-A-1.5: Assignment of protons in the Tartaric Acid structure used in the interpretation 
of 
1
H NMR spectra.  
 
Category / Name of the Proton Total number of proton for that category 
P* 2 
Q* **2 (1H NMR peaks will be missing in gemini-tartrate) 
R 2 
TOTAL for all category 6 Protons 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Q   P HOD  R  DMSO
  
 
Figure-A-1.6: Identification of 
1
H NMR peaks of protons of Tartaric acid (in DMSO-D6) 
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        R 
Figure-A-1.7: Identification of 
1
H NMR peaks of protons of Tartaric acid (in D2O). 
 
N.B.: 
* All the ‘P’ protons and ‘Q’ protons were displaced by deuterium when dissolved in 
D2O. Thus no peak was seen in the spectra obtained from the solution of Tartaric acid in 
D2O. Same applies to the spectra of 16 – 2 – 16.Tartrate solution in D2O. 
 
**During synthesis of the 16 – 2 – 16.Tartrate molecule, both of the protons from the 
two carboxylate group was ionized and gets attached with each of the quaternary ammonium 
head group. Thus the 
1
H NMR peak represents no proton for both of the carboxylate groups 
(ionized form) for this gemini solution in D2O. 
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A-1.4: Atomic details and 
1
H NMR spectral analysis of Malic Acid:  
 
The structure of the Malic Acid (MW = 134.09; Molecular formula: C4H6O5) is –  
 
        P 
Atomic details: 
Total Carbon,  (C)  = 4    R  S 
Total Hydrogen, (H)  = 6 
Total oxygen,  (O) = 5 
       Q           
 Q 
 
 
 
Figure-A-1.8: Assignment of protons in the Malic Acid structure used in the interpretation of 
1
H NMR spectra. 
 
Category / Name of the Proton Total number of proton for that category 
P* 1 
Q* **2 (1H NMR peaks will be missing in gemini-malate) 
R 2 
S 1 
TOTAL for all category 6 Protons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Q     S  P R DMSO R 
 
Figure-A-1.9: Identification of 
1
H NMR peaks of protons of Malic acid (in DMSO-D6) 
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 S            R 
 
Figure-A-1.10: Identification of 
1
H NMR peaks of protons of Malic acid (in D2O). 
 
N.B.: 
* All the ‘P’ proton and ‘Q’ protons were displaced by deuterium when dissolved in 
D2O. Thus no peak was seen in the spectra obtained from the solution of Tartaric acid in 
D2O. Same applies to the spectra of 16 – 2 – 16.Malate solution in D2O. 
 
**During synthesis of the 16 – 2 – 16.Malate molecule, both of the protons from the 
two carboxylate group was ionized and gets attached with each of the quaternary ammonium 
head group. Thus the 
1
H NMR peak represents no proton for both of the carboxylate groups 
(ionized form) for this gemini solution in D2O. 
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A-1.5: Atomic details and 
1
H NMR spectral analysis of Adenylic Acid (AMP):  
 
The structure of the AMP (MW = 347.2, & Molecular formula: C10H14N5O7P) is as 
following –  
 
Atomic details: 
Total Carbon,  (C)  = 10 
Total Hydrogen, (H) = 14  
Total Nitrogen, (N)  = 5 
Total oxygen,  (O)  = 7 
Total Phosphorus, (P) = 1         V 
 
 
           S       T  
 
 
 
 
   R               U 
         M 
    P 
            O        N 
 
 
 
  Q 
 
Figure-A-1.11: Assignment of protons in the Adenylic Acid (AMP) structure used in the 
interpretation of 
1
H NMR spectra.  
 
Category / Name of the Proton Total number of proton for that category 
M 1 
N 1 
O 1 
P 1 
Q* 2 
R* **2 
S 2 
T 1 
U 1 
V* 2 
TOTAL for all category 14 Protons 
 
*All the protons (1H) of Q, R, and V are displaced by deuterium (D) in the 1H NMR spectra of AMP (acid) in D2O  
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U T   M  HOD     N O P S 
 
Figure-A-1.12: Identification of 
1
H NMR peaks of protons of Adenylic acid (in D2O).  
 
 
**N.B. : 
During synthesis of the 16 – 2 – 16.2AMP molecule, only one proton from the 
phosphate group was ionized and gets attached with each of the quaternary ammonium head 
group. Thus, when the 16 – 2 – 16.2AMP was dissolved D2O, the remaining proton of the 
phosphate group of the dissociated counterion was displaced by deuterium. As a result, in the 
1
H NMR spectra, no peak was found for the phosphate group (ionized form) for this gemini 
solution in D2O. 
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A-1.6: Atomic details and 
1
H NMR spectral analysis of Cytidylic Acid (CMP):  
 
The structure of the CMP (MW = 323.20, & Molecular formula: C9H14N3O8P) is as 
following –  
 
Atomic details: 
Total Carbon,  (C)  = 9 
Total Hydrogen, (H)  = 14 
Total Nitrogen, (N)  = 3 
Total oxygen,  (O)  = 8 
Total Phosphorus, (P) = 1   U    V 
 
           S       T  
 
 
 
 
   R  
         M 
    P 
            O      N 
 
 
 
            Q 
 
Figure-A-1.13: Assignment of protons in the Cytidylic Acid (CMP) structure used in the 
interpretation of 
1
H NMR spectra.  
 
Category / Name of the Proton Total number of proton for that category 
M 1 
N 1 
O 1 
P 1 
Q* 2 
R* **2 
S 2 
T 1 
U 1 
V* 2 
TOTAL for all category 14 Protons 
 
* All the protons (1H) of Q, R, and V are displaced by deuterium (D) in the 1H NMR spectra of CMP (acid) in D2O  
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  T  U  M HOD   N  O     P      S  
 
Figure-A-1.14: Identification of 
1
H NMR peaks of protons of Cytidylic acid (in D2O).  
 
 
**N.B. : 
During synthesis of the 16 – 2 – 16.2CMP molecule, only one proton from the 
phosphate group was ionized and gets attached with each of the quaternary ammonium head 
group. Thus, when the 16 – 2 – 16.2CMP was dissolved D2O, the remaining proton of the 
phosphate group of the dissociated counterion was displaced by deuterium. As a result, in the 
1
H NMR spectra, no peak was found for the phosphate group (ionized form) for this gemini 
solution in D2O.  
APPENDIX 
143 
 
A-1.7: Atomic details and HNMR spectral analysis of Uridylic Acid (UMP):  
 
The structure of the UMP (MW = 324.18, & Molecular formula: C9H13N2O9P) is as 
following –  
 
Atomic details: 
Total Carbon,  (C)  = 9 
Total Hydrogen, (H)  = 13 
Total Nitrogen, (N)  = 2 
Total oxygen,  (O)  = 9 
Total Phosphorus, (P) = 1   U 
 
           S       T  
                V 
 
 
 
   R  
         M 
    P 
            O        N 
 
 
 
  Q 
 
Figure-A-1.15: Assignment of protons in the Uridylic Acid (UMP) structure used in the 
interpretation of 
1
H NMR spectra.  
 
Category / Name of the Proton Total number of proton for that category 
M 1 
N 1 
O 1 
P 1 
Q* 2 
R* **2 
S 2 
T 1 
U 1 
V* 1 
TOTAL for all category 13 Protons 
 
* All the protons (1H) of Q, R, and V are displaced by deuterium (D) in the 1H NMR spectra of UMP (acid) in D2O  
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  T  U  M HOD N O P S 
 
Figure-A-1.16: Identification of 
1
H NMR peaks of protons of Uridylic acid (in D2O). 
 
 
**N.B. : 
During synthesis of the 16 – 2 – 16.2UMP molecule, only one proton from the 
phosphate group was ionized and gets attached with each of the quaternary ammonium head 
group. Thus, when the 16 – 2 – 16.2UMP was dissolved D2O, the remaining proton of the 
phosphate group of the dissociated counterion was displaced by deuterium. As a result, in the 
1
H NMR spectra, no peak was found for the phosphate group (ionized form) for this gemini 
solution in D2O.  
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A-1.8: Atomic details and 
1
H NMR spectral analysis of Guanylic Acid (GMP): 
 
The structure of the GMP (MW = 363.2, & Molecular formula: C10H14N5O8P) is as 
following –  
 
Atomic details: 
Total Carbon,  (C)  = 10 
Total Hydrogen, (H)  = 14  
Total Nitrogen, (N)  = 5 
Total oxygen,  (O) = 8 
Total Phosphorus, (P) = 1 
 
           S       T           U 
 
 
 
 
     R               V 
         M 
    P 
            O       N 
 
 
   
  Q 
 
Figure-A-1.17: Assignment of protons in the Guanylic Acid (GMP) structure used in the 
interpretation of 
1
H NMR spectra.  
 
Category / Name of the Proton Total number of proton for that category 
M 1 
N 1 
O 1 
P 1 
Q* 2 
R* **2 
S 2 
T 1 
U* 1 
V* 2 
TOTAL for all category 14 Protons 
 
* All the protons (1H) of Q, R, U, and V are displaced by deuterium (D) in the 1H NMR spectra of UMP (acid) in D2O  
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 T   M  HOD  N O P S 
 
Figure-A-1.18: Identification of 
1
H NMR peaks of protons of Guanylic acid (in D2O). 
 
 
**N.B. : 
During synthesis of the 16 – 2 – 16.2GMP molecule, only one proton from the 
phosphate group was ionized and gets attached with each of the quaternary ammonium head 
group. Thus, when the 16 – 2 – 16.2GMP was dissolved D2O, the remaining proton of the 
phosphate group of the dissociated counterion was displaced by deuterium. As a result, in the 
1
H NMR spectra, no peak was found for the phosphate group (ionized form) for this gemini 
solution in D2O.  
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A-1.9: Atomic details and 
1
H NMR spectral analysis of 16–2–16.2X– (X– = Br–/Cl–): 
 
The structure of the 16–2–16.2X– (MW = 726.9 (Br–) & 638 (Cl–), & Molecular 
formula: C38H82N2X2) is as following –  
 
Atomic details: 
Total Carbon,  (C)  = 38 
Total Hydrogen, (H)  = 82 
Total Nitrogen, (N) = 2 
Total Halide, (X
–
) = 2 (X
–
 = Bromide or Chloride) 
 
 
 
 
 
 
 
 
Figure-A-1.17: Assignment of protons in the 16–2–16.2X– gemini surfactants structure 
(where, X
– 
= Br
–
/Cl
–
) used in the interpretation of 
1
H NMR spectra.  
 
Category / Class of the Proton Total number of proton for that category 
A 6 
B 4 
C 48 
D 4 
E 4 
F 4 
G 12 
TOTAL for all categories 82 Protons 
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Figure-A-1.18: Identification of 
1
H NMR peaks of protons of 16–2–16.2X– gemini 
surfactants (where, X
– 
= Br
–
/Cl
–
) 
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A-2.1: Complete 
1
H NMR Spectra of 16-2-16 series of GSs with various counterions: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-A-2.1: 
1
H NMR spectra of 16-2-16.2Br 
–
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Figure-A-2.2: 
1
H NMR spectra of 16-2-16.2Cl 
–
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 D2O peak 
 
 
6H of two acetate ions (CH3COO
–
)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-A-2.3: 
1
H NMR spectra of 16-2-16.2Ac 
–
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Figure-A-2.4: 
1
H NMR spectra of 16-2-16.2AMP 
–
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Figure-A-2.5: 
1
H NMR spectra of 16-2-16.2CMP 
–
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Figure-A-2.6: 
1
H NMR spectra of 16-2-16.2UMP 
–
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Figure-A-2.7: 
1
H NMR spectra of 16-2-16.2GMP 
–
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 D2O peak 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-A-2.8: 
1
H NMR spectra of 16-2-16.Tartrate 
– –
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 D2O peak 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-A-2.9: 
1
H NMR spectra of 16-2-16.Malate 
– –
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Table-A-3.1: Solubility test data for organic counterions 
Properties 
Counterion (ACIDIC form)* 
Tartaric 
Acid 
Malic 
Acid 
AMP.H2O CMP UMP GMP 
Molar Mass (g/mole) 150.08 134.09 365.24 323.20 324.18 363.20 
Solubility in water 
(‘x’ mg / 100 μL) 
167 mg  
@ 40
0
C 
58.8 mg 
@ 25
0
C 
33 mg 
@ 40
0
C 
10 mg 
@ 35
0
C 
40 mg 
@ 25
0
C 
6.7 mg 
@ 60
0
C 
 # Hydroxyl Group 2 1 2 2 2 2 
 
* AMP.H2O: Adenylic acid, CMP: Cytidylic acid, UMP: Uridylic acid, GMP: Guanidylic acid  
 
 
Table-A-3.2: Results of comparative solubility conditions for 16-2-16 series of GSs 
Gemini Solutions 
(1.5 mM, 10 mL) 
Sonication time required for the GSs to 
get dissolved from solid crystals @ 55
0
C 
(minutes) 
Inference / Verdict 
16 – 2 – 16 . 2Br – 50 Soluble 
16 – 2 – 16 . 2Cl – 25 Soluble 
16 – 2 – 16 . 2AMP – 30 Soluble 
16 – 2 – 16 . 2CMP – 25 Soluble 
16 – 2 – 16 . 2UMP – < 1, at 250C, no sonication required Readily Soluble 
16 – 2 – 16 . 2GMP – 75 (+ Vortexing) Sparingly Soluble 
16 – 2 – 16 . Tartrate – – 40 Soluble 
16 – 2 – 16 . Malate – – < 10 (Was soluble in 250C) Readily Soluble 
 
 
Table-A-3.3: Critical Packing Parameters of 16-2-16 series of GS with different counterions 
Gemini  
Surfactants 
Average Critical 
Packing Parameter,  
CPP = V / a0.lC 
Aggregate Structure according to 
CPP 
16-2-16.2Br 
–
 0.34 Spherical micelles 
16-2-16.2Cl 
–
 0.32 Spherical micelles 
16-2-16.2AMP 
–
 0.33 Spherical micelles 
16-2-16.2CMP 
–
 0.39 Cylindrical or rod shape micelles 
16-2-16.2UMP 
–
 0.34 Spherical micelles 
16-2-16.2GMP 
–
 0.53 Cylindrical or rod shape micelles 
16-2-16.Tartrate 
– 
 
–
 0.43 Cylindrical or rod shape micelles 
16-2-16.Malate 
– 
 
–
 0.50 Cylindrical or rod shape micelles 
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A-3.4.1 Viscosity measurement 
The viscosity of the gemini solutions were measured using a Gilmont Falling ball 
viscometer (size #2, GV 2200, Thermo Scientific, USA) at 55
0
C. The temperature was 
controlled at a precision of ±0.05
0
C using an immersion circulating water bath (VWR, USA). 
Saturated aqueous solutions (~1.5 mM, >> CMC for all surfactants) were prepared, 
separately, for each gemini surfactant, by sonication at 55
0
C and the gemini solutions were 
inserted in the viscometer assembly along with the stainless steel ball, and the time (in 
milliseconds) required for the ball to travel across the start and stop points of the viscometer 
was recorded. All viscosity measurements were repeated in triplicate and the average is 
reported. Viscosities were calculated according to (Equation-A-3.1) as following: 
 
Viscosity of a liquid (in centipoise units), μ = K(Db – DW) / t            A-3.1 
Where, 
 K = Viscometer constant (for viscometer size #2, K = 3.3 was used as provided) 
 Db = Density of the stainless steel ball (8.02 g/mL) 
DW = Density of Milli Q water at experimental temperature (0.98 g/mL @ 55
0
C) 
t = Required time (in minutes) for the ball to travel across the start – stop points 
 
 
A-3.4.2 Foam ability and foam stability measurement 
Foamability and foam-stability of the gemini surfactants were studied using a 
previously reported method [80, 81, 203, 204]. Twenty milliliters of gemini solution (1.5 mM 
>> CMC for all surfactants) at 55
0
C was placed into a calibrated 100 mL graduated cylinder 
equipped with a stopper. The solution was shaken in the cylinder uniformly and vigorously 
for 10 seconds and the volume of foam produced was recorded at 0 min, 10 min and 20 min. 
The initial volume (0 min) of the foam produced was measured as foamability of the 
surfactant, while foam stability was determined from the remaining foam at 10 and 20 
minutes [204]. All the measurements of foamability and foam stability were repeated in 
duplicate for each gemini. 
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Table-A-3.4: Viscosity, foam-ability & foam stability data of 16-2-16 series of gemini 
surfactant solutions with eight different counterions 
 
Name of the GS 
solution 
(0.1 % or 1.5 mM) 
Average 
Viscosity* 
(cP) 
Ave. of the Initial 
volume of the 
foam produced         
(mL) 
Ave. Foam 
stability  
after 10 mins       
 (%) 
Ave. Foam 
stability  
after 20 mins          
(%) 
16-2-16.2Br 
–
 1.09 6.7 49.6 20.3 
16-2-16.2Cl 
–
 1.06 13 82.4 53.3 
16-2-16.2AMP 
–
 0.98 10.6 89.9 46.7 
16-2-16.2CMP 
–
 0.94 12.4 90.1 50.1 
16-2-16.2UMP 
–
 0.97 11.3 88.7 52.3 
16-2-16.2GMP 
–
 0.96 10 85.8 38.8 
16-2-16.Tartrate 
– –
 0.97 9.4 84.3 33 
16-2-16.Malate 
– –
 1.03 10.7 86.7 62.6 
 
* Viscosity of milli Q water was found 0.47 cP   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-A-3.1: Graphical representations of the foaming volume (foamability) produced by 
the 16-2-16 series of gemini at different time intervals 
 
 
APPENDIX 
161 
 
Table-A-3.5: Recorded values & parameters of all the extractions for pNN9 plasmid 
Extraction 
Number 
Extracted 
Sample 
Extraction Kit Used 
Sample conc. 
(ng/ μL) 
A260/280  
(Nano-drop) 
Extraction-1 
OD600 = 1.66 
Sample – 1 E.Z.N.A.® Maxi 179.2 1.81 
Sample – 2 E.Z.N.A.® Maxi 193.2 1.83 
Extraction-2 
OD600 = 1.54 
Sample – 1 E.Z.N.A.® Maxi 104.4 1.85 
Sample – 2 E.Z.N.A.® Maxi 92.5 1.80 
Sample – 3 E.Z.N.A.® Maxi 97.1 1.82 
Extraction-3 
OD600 = 1.82 
Sample – 1 E.Z.N.A.® Endo-Free Maxi 523.3 1.88 
Sample – 2 E.Z.N.A.® Endo-Free Maxi 656.1 1.91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-A-3.2: UV image of the agarose gel after AGE for size confirmation of pNN9 
plasmid 
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